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Tuberculosis is one of the most deadly infectious diseases currently plaguing the global community. 
Unfortunately, lack of accessible, reliable and affordable diagnostic tools in the high disease burden, 
and resource poor regions such as Sub-Saharan Africa has hampered efforts to eradicate the epidemic. 
This study documents the development of a microfluidic platform called Light Forge, which is 
capable of detecting genetic drug resistance signatures in M.tuberculosis DNA. The first phase of this 
study involved a molecular drug susceptibility assay on 7 strains of M.tuberculosis using the high 
resolution melt analysis at the rpoB, katG, mab-inhA and gyrA loci with the Light Cycler96 . These 
findings compared with phenotypic drug susceptibility testing and Sanger sequencing. The results 
from the preliminary tests showed that the commercial system could detect positive strains at 
sensitivity estimates of 86%, 17% , 0% and 100%  for rpoB, katG, mab-inhA and gyrA respectively. 
Detection of non-synonymous mutation in gyrA region for all test strains halted further testing. The 
rpoB gene was selected for on chip profiling with the Light Forge system due to the higher sensitivity. 
The results from the Light Forge showed that the system was capable of detecting test strains with 
100% sensitivity, with modest reproducibility and correspondence with the phenotypic drug 
susceptibility profiles and the sequencing results. A microfluidic TB assay based on the Light Forge 
system is on the horizon based on the findings of the study. However, more work is required to 
incorporate other genes and ultimately design the best-equipped device for the clinical setting.
CHAPTER 1: INTRODUCTION 
The emergence of drug resistant strains of M.tuberculosis demands an increase in the diagnostic 
capacity of health care delivery programs. Drug resistance leads to treatment failure, increasing the 
mortality and disease transmission rates 
1
. Increasing diagnostic capacity is a major proponent in 
achieving the goals of the STOP TB strategy. The strategy aims to reduce TB transmission by 80%, 
TB related deaths by 90% and TB associated costs to the patients by 100% before the year 2030 
2
. 
These are steep goals, which will require a concerted effort from all TB stakeholders ranging from the 
pharmaceutical companies, governmental agencies and technological institutions right up to the 
patients.  
This thesis describes the development of a microfluidic assay for the detection of drug resistance 
linked mutations in M.tuberculosis. Microfluidics exploits the miniaturization of reactions in an 
integrated manner to deliver fast, efficient assays with increased resolution of the product. This 
introductory chapter is aimed at highlighting the important aspects of tuberculosis disease, more so its 
synergistic interaction with HIV/AIDS. I further proceed to document the various drugs used to treat 
the many variations of this disease. A summary of the current diagnostic tools used in tuberculosis 
research ensures. The chapter concludes by an expose into the arena of microfluidics, with emphasis 
on devices performing nucleic acid amplification. Chapter 2 shows the methodologies used in the 
development of the assay from the preliminary to the testing phase. Chapter 3 provides a sequential 
and chronological presentation of the results from the commercial system leading up to the findings 
from the Light Forge system. Results from the standard methods are included to verify the 
observations. The final chapter, chapter 4, discusses the findings of the experiment. It highlights the 
advances the Light Forge device is making whilst suggesting areas in which assay can be further 
improved. This study is a collaborative effort with Mr Tawanda Mandizvo from the Kwazulu Natal 
Research Institute of Tuberculosis and HIV/AIDS, Balagadde lab. 
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 1.1 HIV/TB endemic 
Tuberculosis (TB) is a disease caused by infection with Mycobacterium 
tuberculosis(M.tuberculosis)s, which typically infects the lungs (pulmonary TB) but can also infect 
other organs including the kidneys, spinal cord, and brain (extra pulmonary TB) 
3
. TB can be either 
latent or active, with the former referring to a state in which the M.tuberculosis is in a dormant, non-
infectious phase. Active TB is when the bacteria are actively dividing in the host thus are easily 
transmitted 
4
. A third of the global population suffers from latent TB. However, due to the body’s 
defence system, clinical symptoms are the result of an immune-compromising event such as the onset 
of HIV/AIDS. About 9 million TB cases were reported in 2012 alone, with 1.3 million TB related 
deaths worldwide 
5
. Even though this disease is treatable, it remains a challenge to the global 
community over a century since its discovery. The co-infection of TB and HIV-AIDS (“cursed duet”) 
is a major challenge in resource-limited settings, particularly in Asia and Sub Saharan Africa. This is 
cemented by the realisation that even though South Africa has less than 1% of the World’s population, 
it is responsible for more than 25% of global HIV-TB co-infection cases 
6
. Compared with other 
countries, such as USA (high income), China (upper middle income), India (lower middle income) 
and Zimbabwe (low income), South Africa (upper middle income) have the highest incidence of TB 
in spite of obvious economic and population advantages to the aforementioned countries. In the mid-
90s, countries in the Sub-Saharan Africa had a boom in TB incidences (Figure 1) catalysed by an 
increase in the rate of HIV infection cases. This is in contrast to the USA, China and India, which 
show a gradual decrease in TB cases even to date. Perhaps issues such as poverty, inequality and 
social turbulences coupled to a lack of standard health care could have led to more HIV related TB 
cases in South Africa 
7
. A study recently showed that HIV positive individuals of  African descent  
had a 2.5 fold chance of developing tuberculosis disease in comparison to those of Caucasian ancestry 
8
. The observation was a result of a mutation in the gene that produces the macrophage migration 
inhibitory factor (MIF). MIF is implicated inflammation and ultimately infection control. Such a 
finding implies that the biological make up of an individual might predispose them to disease, but 
more research is required to support this claim.  
Studies have shown that within the human host, the two pathogens—M. tuberculosis and HIV— 
develop a mutual interaction,  leading to the fatal disruption of the immune functions when unabated 
9
. Infection with HIV increases the risk of activating latent TB infection into active disease by 20-fold 
10
. In the following passage, a brief description of the biology of the TB/HIV co-infection, its effect on 




Figure 1: TB incidence rates variation in South Africa, India, USA, China and Zimbabwe adapted from 
the World Bank 
11
. 
The graph above shows that the TB incidence cases in the USA have been relatively constant for the 
for the past two decades. Over the same period, China and India gradually reduced the incidences of 
TB disease but cases are still higher than the rates observed in the USA. South Africa and Zimbabwe, 
both in the sub-Saharan region, show increase in the incidences of TB from 1995. This increase 
correlated with the increase in HIV incidences in the region. The rates peaked in 2004 for Zimbabwe 
and 2007 for South Africa, after which steady declines ensured because of improved intervention by 
the TB control programs. However, the current rates are still too high in comparison to global 
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1.1.1 Biology of TB/HIV interaction 
One of the most critical outcomes of an untreated HIV infection is the reduction in the number of 
CD4
+
 T cells, which increases the risk of latent TB advancing to active TB disease. Coupled  to added 
susceptibility to exogenous superinfecting  TB strains 
10
. Tumour Necrosis Factor (TNF) is a cytokine 
that is produced by macrophages or monocytes in response to infection 
12
. It has been implicated in 
the caseous necrosis(aggregation of host immune cells to eliminate M.tuberculosis)—observed during 
infection with TB—that helps to ensure short and long term control of the pathogen 
13
. HIV infection 
inhibits killing of M. tuberculosis by macrophages mediated by  TNF  
14
. Macrophages activate a 
programmed cell death pathway, creating an acidic cellular environment that eliminates the 
M.tuberculosis. When HIV infects the macrophage, it tends to halt the programmed cell death, 
allowing the cell to persist 
15
.This invariably increases the pathogenesis of M.tuberculosis. In addition, 
HIV infection increases the expression of receptors that facilitate the entry of M.tuberculosis   into the 
macrophages, allowing the dispersion of M.tuberculosis throughout the host 
16
. Typically, TB 
infection is contained within granulomas—highly stratified cellular confines that prevent 
dissemination of M.tuberculosis cells and ultimately help eradicate the infection. Granulomas also 
serve as a classical indication of M.tuberculosis infection. HIV infection compromises the 
containment of M.tuberculosis by altering the granuloma structure.  This can be achieved by 
hampering recruitment of new cells to the granulomas, causing them to be more porous to external 




Interestingly, some studies claim that TB disease has a negative effect on HIV infection progression 
to AIDS although this claim is not completely substantiated 
10
.  On the contrary, an elevated viral 
replication rate has been observed in sites with a highly localised M.tuberculosis population 
18
. This is 
observed in alveolar  macrophages—the primary target cells for TB infection—were elevated rates of 
HIV replication are observed, spiking transmissions of M.tuberculosis from infected macrophages to 
T cells
10
. It is known that TNF is released by the immune system to  arrest bacterial growth but 
unfortunately it also activates  HIV replication in macrophages, thus the body is essentially 
predisposed to susceptibility to HIV by a positive response to the TB pathogen 
19
.  
Dendritic cells (DC), found on the skin and mucosal surfaces, are responsible for trapping antigens 
and presenting them to the T cells to activate the adaptive immune response 
20
. Both TB and HIV 
infections  repress the host’s  pro-immunity activities using different mechanisms, specifically the 
DC-specific C-type lectin receptor (DC-SIGN). M.tuberculosis is captured via this receptor and 
internalised by the cells, where it has been shown to down-regulate  the response of the immune 
system by suppressing cytokines responsible for pathogen eradication such as IL-12 and TNF 
21
. HIV 
on the other hand, hybridizes to the DC-SIGN receptor through its gp120 protein, facilitating the 
efficient distribution of this virus throughout the host. Targeting of these cells by TB and HIV greatly 
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limits the controlling ability of the immune system and further complicates efforts to diagnose each of 
the pathogens as highlighted in the subsequent passage. 
1.1.2 Implication of TB/HIV coinfection on diagnosis  
HIV co-infection with TB elicits a marked negative effect on their clinical diagnosis, perhaps a 
consequence of TB/HIV interaction. Firstly, HIV positive patients typically have low tubercle bacilli 
numbers in their sputum and develop more defined extra-pulmonary TB, leading to sputum negative 
microscopy results 
22
. Clinicians’ use symptom screening in resource constrained countries as a 
method to determine the TB status of patients, prominently relying on a cough sustained for a period 
exceeding 3 weeks as high confidence marker for active TB disease. However, for patients living with 
HIV/AIDS, this symptom often has a low sensitivity for TB 
23
. Coupling  night sweats and fevers to 
the persistent cough leads to a useful marker in clinical diagnosis of TB disease. Nevertheless care 
should be taken as reliance on these symptoms invariably increases the chances of false detection of 
TB since the symptoms are not  specific to TB disease 
23
. Infection with HIV serves as an avenue for a 
myriad of opportunistic infections, confounding the interpretation of findings from chest X-rays 
24
. In 
spite of these glaring limitations, the diagnostic algorithms for HIV positive and HIV negative 
patients are still largely the same for most national disease monitoring programmes. The reality of the 
situation is that it is difficult to arrive at a high confidence diagnosis without the use of culture based 
methods which require longer time periods (3 to 8 weeks), dedicated facilities or more expensive 
molecular techniques that can detect DNA or RNA TB markers in shorter time periods. HIV infection 
is easy to detect in bodily fluids such as saliva or blood of the patient using a wide array of methods 
25
. A thorough scan of the literatures shows that tuberculosis infection does not impede HIV 
diagnosis.   
1.1.3 Treatment of TB/HIV coinfection 
Discovery of the highly active antiretroviral therapy (HAART) has improved the clinical outcomes as 
shown by the decline of the number of deaths in study cohorts in the United States of America from 
987 to 78 in 6 years 
26
. The same trend was observed in South Africa 
27
, in which the better survival 
rates were attributed to HAART and comprehensive TB therapy 
28
. Optimal use of both these 
regimens leads to  effective disease management. This raises one of the biggest challenges in TB/HIV 
treatment: when to initiate HAART for patients already receiving TB treatments. This decision is 
complicated by the fact that drugs that are  in the rifamycin class and routinely used in TB therapy—
including rifampin and rifabutin—negatively interact with protease inhibitors (PIs) and non-
nucleoside reverse transcriptase Inhibitors (NNRTI) that are used in HIV treatment
29
. Short course TB 
therapy is a fully supervised 6 month  regimen aimed at reducing the cost of treatment as well as 
increasing patient adherence 
30
. Short course therapy involves 2 months of daily rifampin, isoniazid, 
pyrazinamide and ethambutol, followed by 4 months of isoniazid and rifampin twice a week. There is 
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minimal description of how the HIV infected patients respond to the short course therapy for TB 
31
, 
with some studies suggesting that it leads to lower relapse rates for HIV positive patients 
32
. 
In order to address the challenges encountered in effective treatment of TB/HIV coinfection, 
treatment plans typically adhere to the notion that TB treatment takes precedence over that of HIV 
33
.  
More often than not, this stance requires adjustments, by taking into account CD4+ counts and drug 
resistance profiles of the M. tuberculosis of the patient. Patients with CD4+ counts greater than 200 
cells/ml start HAART after completion of anti-TB therapy, whereas patients with CD4+ counts less 
than100 cells/ml have to receive HAART shortly after starting anti-TB therapy 
33
.  In spite of the 
several nuances, Dean et al showed that early initiation of HAART leads to fewer deaths and 
instances of debilitating TB disease 
34
. On the contrary, early initiation of HAART increases the risk 
of developing Immune Reconstitution Inflammation Syndrome (IRIS), which is a paradoxical 
immune response to HAART were the clinical condition worsens due to an excessive immune 
sensitivity to infectious and non-infectious antigens 
35
. However, in cases of TB/HIV coinfection, 
IRIS can lead to an elevated drug toxicity and reduced  efficacy of anti-TB therapy 
36
. All these 
dynamics serve to illustrate that coinfection of TB and HIV invariably complicates the treatment 
planning and outcomes for the patients. 
It is clear that TB/HIV confection is a threat to the management of these diseases. Through their 
pseudo-symbiotic and largely elusive interaction within the host, they have added several layers of 
complexity to their respective diagnoses and treatment plans. Meaningful efforts should be channelled 
towards preventing future HIV and TB transmission, improving all of the current treatment plans in 
high disease burden areas as a cooperative effort from governments, cooperates and the communities 
at large without delay. 
1.2 Tuberculosis drugs  
Tuberculosis has afflicted humankind for many centuries. Physicians have treated patients in many 
different ways over the years. One of the early treatments involved a combination of prolonged 
exposure to the sun, fresh air and assuming the proper gait 
37
. This strategy yielded moderate success 
probably because patients lungs were not agitated by pollutants found in the cities,  and the 
prescription of rest and prescribed posture allowed the natural healing of TB lesions 
37
. This also 
made it easier to isolate patients who were releasing TB-pathogen packed aerosols. Clinicians in the 
early 1900s  also resorted to collapsing the lungs of the patients to address TB disease as a last 
alternative for grave cases 
38
. This was borne from the observation that healing TB lung cavities close 
or die off. The major assumption being  by seizing function of part or the entire lung, perhaps the 
patients would recover. Lung collapsing was performed by either a pneumothorax (filling the 
interplural space with air or nitrogen) 
39
, phrenic paralysis (inhibiting function of the phrenic nerve, 
which controls lung expansion) 
40




. Even though these approaches may seem bizarre and peculiar to a modern reader, they helped 
reduce the lung capacity, accelerating the repair of cavities in the lungs and reducing the bacterial load 
expelled during exhalation
37
.  The above methods were rapidly replaced by more scientific remedies 
when Robert Koch proved that tuberculosis disease was caused by a bacterial pathogenic agent 
42
. 
This paved the path for the development of several antibacterial agents for treating the disease. 
The goal of chemotherapy  is to reduce the pathogenic load whilst mitigating the effects of pathogen 
metabolic activity on the host. There exists a wide range of anti-TB drugs, developed in the 1940s. 
The desired outcome of the chemotherapy is to eradicate all multiplying bacteria, prevent 
development of TB drug resistance and achieve host sterility to avoid clinical  relapse 
43
. Combination 
treatment allows eradication bacteria multiplying at different rates. In the following section, the 
various drugs administered for different forms of the TB diseases (first- and second-line drugs), while 
highlighting potential drugs, which are still in the trial phases, are confabulated.  
1.2.1 Firs line anti-TB drugs 
Four drugs (isoniazid, rifampin, pyrazinamide and ethambutol) constitute first line tuberculosis 
therapy. These drugs are for TB treatment-naïve patients with the operating assumption that the 
infection is with drug-susceptible or treatable strain(s) of Mycobacterium tuberculosis. The treatment 
plan  involves 2 months of intensive treatment with all four drugs followed by a continuation phase 
lasting  4 months with only isoniazid and rifampin 
44
. These agents represent the first response to the 
detection of infection, commonly referred to as Group 1 drugs. 
1.2.2 Isoniazid 
Isoniazid, a nicotinamide prodrug, was discovered in 1952 and has potent bactericidal activity against 
Mycobacterium tuberculosis 
45
. It is the most prescribed anti-TB drug. Isoniazid is readily absorbed 
by host cells and is passively taken up by M.tuberculosis 
46
. Studies have shown that it interferes with 
several cellular functions, particularly nucleic acid synthesis 
47
. However its  potency against 
M.tuberculosis is linked to inhibition of mycolic acid synthesis 
48
. This effect is achieved when the 
oxidised form of isoniazid binds to the Enoyl Acyl Carrier Protein (ACP) reductase InhA 
49
, a critical 
enzyme in the fatty acid synthesis complex. NAD is a coenzyme which exists in its oxidized (NAD
+
) 
or reduced form (NADH) functioning as an electron transfer factor in redox processes 
50
. It is 
involved in cellular regulations such as energy generation, DNA transcription and repair. Thus the 
interaction of isoniazid with bound NAD is thought to dislodge this metabolite from the active form 
of reductase 
51
, halting the enzymatic process. Unfortunately, the overuse of this drug has led to the 
development of resistance. In 50-80% of the cases, drug resistant clinical isolates harboured a point 
mutation in the katG gene, specifically a threonine substitution with serine at residue 315 
43
. 
Resistance to isoniazid has also been shown to be due to mutations in the inhA gene or its promoter 
mab-InhA, maintaining enzyme functionality but reducing affinity to NADH substrate perhaps by 
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using a different substrate 
52
 . Mutations in other genes such as ndh , kasA ,aphC, oxyR have been 
implicated in low to moderate events of isoniazid resistance 
53
. In spite of all this knowledge, some 
clinical isolates with phenotypic resistance lacking mutations in any of the known genes have been 




A member of the rifamycin family, rifampin is a synthetic drug, which is a vital component of anti-TB 
drug regimens. It exhibits a characteristic delayed bactericidal activity in comparison to isoniazid, 
making it suitable for killing bacteria which continue to survive (albeit in a diminished metabolic 
state) for long periods during chemotherapy 
55
. Due to its lipid-like properties, rifampin can be easily 
transported  into the extracellular environment of M.tuberculosis 
52
. Its bactericidal activity is 
attributed to the ability to bind to the bacterial RNA polymerase inhibiting transcription 
43
, although 
the exact mechanism of this action is yet to be fully understood.  Similar to isoniazid, prolonged and 
munificent prescription of the drug has led to development of resistance. In over 90% of rifampin 
resistant isolates, point mutations were detected in a highly variable 81bp region of the rpoB gene, 
encompassed in codon 507 to 533 
53
. Not all the rifampin resistant strains exhibit mutations in this 
region and more studies are required to allow full comprehension of resistance conferring gene 
mutations.  
1.2.4 Pyrazinamide 
Pyrazinamide is a member of the nicotinamide group of drugs together with isoniazid. Similar to 
isoniazid, it is a prodrug that is converted to its active form, pyrazinoic acid by the activity of 
pyrazinamidase 
56
. It shows high efficacy against slowly dividing bacteria in a quasi-dormant state 
under acidic conditions typically found in phagosomes 
57
. However, the killing effect is sustained for 
up to 2 months only during treatment 
58
. The accumulation of pyrazinoic acid in the cytoplasm is 
thought to lead to the disruption of the proton motive force due to the low intracellular pH 
59
. 
Pyrazinamide has been shown to inhibit trans-translation, a pathway designed to ensure production of  
correct functional proteins and in some instances gene expression in bacteria 
60
. Resistance to 
pyrazinamide is generally attributed to mutations in the gene pncA, which codes for the production of 
the afore mentioned pyrazinamidase 
43
. Drug resistance is linked to mutations throughout the 561bp 
region coding for this enzyme and its 82bp promoter region . This  complicates development of a 
simple assay for detection of genomic signatures of pyrazinamide resistance 
61
. As with the 
aforementioned anti-TB drugs, not all resistance can be attributed to mutations in the pncA region,  






Ethambutol  was discovered in 1961 as an anti-TB drug and has since been incorporated into first line 
TB therapy 
43
. A member of the alkanolamines, this drug targets dividing bacteria and is incorporated 
into the combination treatment  to minimise development of resistance to the other first line drugs 
despite possessing minimal sterilizing ability 
62
. It interferes with arabinogalactan synthesis by 
preventing chain elongation of this biological polymer 
63
. It has also been reported to interfere with 
other cellular activities such as phospholipid synthesis 
64
. Point mutations at codon 306 of the embB 
gene are responsible for resistance to this agent for about 50% of the resistant cases 
65
. Other cases 
have been attributed to various factors such as  mutations in the embCA operon, although cases of 
resistance which cannot be attributed to any known mutations are still very frequent 
43
. 
Clinical resistance to the aforementioned antibiotics can be a result of several genetic or epigenetic 
factors. Firstly, some M.tuberculosis strains are naturally or intrinsically resistant to these agents as a 
result of chemical and physical modifications of their cell wall 
66
. Secondly, M.tuberculosis 
subpopulations can display an epigenetic phenomenon called persistence, which is caused by non-
inheritable changes that alter gene expression with no alterations in the DNA code 
67
. This is most 
likely a result of the re-arrangement of the cellular responses by epigenetic modulators via DNA 
methylation mechanisms and modification of histones 
68
. This leads to a diminished metabolism and 
growth for protracted periods of time 
69
. Finally, most cases of drug resistance are a result of acquired 
resistance. It occurs when exposure to the discussed antibiotic agents selects for a subpopulation of 
mycobacteria harbouring advantageous mutations, that eventually thrive in the presence of the drug 
70
. 
This form of resistance is unique in that it occurs at highly predictable rates for the first line anti-TB 
drugs. For instance David et al reported that for isoniazid, rifampin, ethambutol, 190, 3 and 843 cells 
per 300 million a generation develop mutations upon drug exposure respectively 
71
. When resistance 
arises during patient treatment, some clinicians respond addition of streptomycin to the regimen. 
However, this drug  has been shown to further accelerate  the development of clinical resistance 
72
. 
There are several variations of clinical resistance in tuberculosis disease. Multidrug resistant TB 
(MDR-TB) is when the M.tuberculosis strain is resistant to isoniazid and rifampin 
70
. Acquisition of 
an MDR-TB strain by a patient leads to failure of the first line treatment drugs. Another form of TB 
resistance in Extensively Drug Resistant TB (XDR-TB) which is basically MDR with added 
resistance to any of the fluoroquinolones and one of the injectable drugs such as amikacin, 
capreomycin and kanamycin 
73
. Cases of MDR- and XDR-TB were reported in 2006 in the province 
of KwaZulu-Natal, South Africa 
74
. Emergence of these strains coincided with alarming rates of 
mortality in the same study. In such instances, clinicians are forced to switch to second line TB Drugs 













Third Line Drugs 
Isoniazid Streptomycin Ciprofloxacin Paraminosalicyclic 
acid 
Clofazimine 
Rifampin Kanamycin Levofloxacin Cycloserine Amoxicillin/Clavulanate
$ 




Ofloxacin Ethionamide Clarithromycin 
 Viomycin
* 
Gatifloxacin Prothionamide  
   Thioacetazone  
   Linezolid  
Table 1: Second and Third Line Drugs used in TB treatment. The table above shows the various 
drugs used to treat of infections by M.tuberculosis. Group 1 drugs are first line or initial treatment 
agents. Group 2 to 4 make up the second line drugs. These drugs replace the first line drugs when they 
fail to treat the infection. Group 3 drugs are third line drugs. Prescription of these agents is normally 




drugs used in optimised combination ,information  from 
44
. 
The term second line drug is allotted to a drug due to either the limited availability of clinical data, 
unfavourable pharmacokinetic profile or increased incidence of severe side reactions 
75
. In most cases, 
treatment of MDR and XDR TB strains with these drugs has yielded suboptimal outcomes associated 
with elevated toxicity levels 
76
. Kuban et al studied the effectiveness of 12 months treatment course 
that included gatifloxacin, clofazimine, prothionamide, ethambutol, and pyrazinamide throughout 
supplemented with isoniazid and kanamycin during the first 4 intensive months. Although a cure rate 
of 89%  was observed, almost half of the patients developed hearing impairment
77
. Drugs in Group 5, 
loosely referred to as third line drugs  treat the most lethal form of the disease, Totally Drug Resistant 
(TDR) TB. This acronym describes strains of MDR which are resistant to all known second line drugs 
78
. TDR-TB was first detected in Italy in the year 2007 
79
. In such cases treatment is administered for a 
minimum of 18 months but very little data exists on treatment efficacy thus this option is only used as 
a last resort 
75
. Cases of TDR-TB were recently reported in South Africa in 2013 and it is clear that 
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the national TB management infrastructure needs to be revamped to prepare for the inevitable 
outbreak of these strains 
80
. 
Another variation in resistance observed with  M.tuberculosis is heteroresistance, defined as the 
condition in which a single patient is infected simultaneously by a drug resistant and drug susceptible 
strains of the pathogen 
81
. Convention states that for a strain to be categorised as drug resistant, is 
should be above 1% of the total population as this is higher than resistant strains arising from 
spontaneous mutation. Mutations tend to be associated with a fitness cost to the pathogen, explaining 
why these confounding occurrences are missed by the extensively used culture methods 
82
. This 
highlights the need for new methods for M.tuberculosis detection which can account for smaller 
populations, for example it has been reported that the earliest mutant in an isoniazid culture occurs at 
a rate of 1 in 10
8
 cells per generation 
83
. Early pathogen detection might lead to improved therapeutic 
outcomes and an in depth understanding of the pathogenesis of the disease within the host. 
Amplification of heteroresistant DNA samples produces a wide range of amplicons ranging from the 
wild type to the mutant 
84
. This was shown when an isoniazid heteroresistant sample run in 10 parallel 
reactions from the same PCR master mix produced highly variable products 
84
. Even though it was 
difficult to determine which replicate would yield a particular ratio of the amplicons, the pronounced 
variation was reproducible. Stochastic variations during the early stages of the PCR when the DNA 
forming complex is being assembled have been suggested to cause the deviant behaviour  
85
. This 
limitation can be addressed by using digital PCR to detect heteroresistance as shown by Phowlat using 
clinical isolates 
86
. It is important to understand the clinical significance of heteroresistance, as this 
can potentially lead to more personalized therapies, which may be more effective in fighting the TB 
epidemic. Morand suggested that heteroresistance is a result of evolution, which allows a section of 
the microorganisms to acquire the mutation that allows survival before the entire population becomes 
resistant 
87
. Thus, it serves as a precursor to full resistance within the host, suggesting interception 
might halt disease progression. Heteroresistance has also been implicated in increased resistance to 
other antibiotics, thus it might be an ancient drug evasion strategy 
88
.  
First line therapy still has efficacy against susceptible TB strains, but emergence of MDR, XDR and 
TDR-TB highlights the need for new drugs. An interesting candidate drug is bedaquiline, currently 
used to treat MDR-TB as the final option 
75
. In spite of encouraging results from earlier trials, it is still 
relegated to compassionate use as it has been reported to negatively interfere with neural activity of 
the heart 
89
. Other drugs—including nitroimidazoles, fluoroquinolones and rifamycins—are currently 
being tested and repurposed to the improve efficacy of the combination therapy, seeding hope for 
better treatment outcomes in the near future.  
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1.3 TB Diagnosis approaches 
Tuberculosis diagnosis is a vital cog in TB control programs as it encompasses the various methods 
used for case detection. It is very important in the algorithms used by national control programs as it 
allows early treatment of the TB disease, preventing transmission. Countries such as USA and the 
more affluent European nations have successfully controlled TB by availing abundant human 
resources, health care systems and the necessary funding to support diverse efforts to control this 
disease 
90
. Unfortunately, most high incidence areas lack most if not all of these resources, casting a 
desperate state of affairs. Inadequate tools and appropriate laboratory services mean that a large 
portion of tuberculosis disease will be uncounted. A large proportion of patients will receive 
unnecessary treatement for tuberculosis based on their clinical presentation as it takes long for culture 
results to come back. Such a decision fuels poor resource utilization. There is also a group of patients 
who receive a delayed diagnosis due to a wide range of socioeconomic factors, increasing the chances 
of death and disease transmission  
91
.  
Disease detection in TB  largely occurs when patients with  a continual cough for periods of a few 
weeks present themselves to health care facilities 
92
. The initial approaches involve  testing the patient  
with methods ranging from immunological tests such as tuberculin skin test, imaging techniques such 
as sputum smear microscopy (SSM), chest radiographic examinations, and bacteriological assays such 
as culture based testing to molecular diagnostic such as the Xpert/MTB device. These methods have 
several levels of impact and applicability in TB control. The vast range of existing methods is 
testament of the major advances t in TB diagnosis, over the last 3 decades.  
The next section seeks to discuss these diagnosis methods and their unfortunate drawbacks. It 
proceeds to highlight the assays that are still in the testing phase and concludes by suggesting the 
issues the ultimate TB diagnosis will have to address to contribute to the eradication of this disease in 
the most meaningful way.  
1.3.1 Tuberculosis detection 
Tuberculosis is thought to have latently infected one third of the human population, with only 10% of 
these individuals developing active disease 
93
. This has led to an increased level of attention towards 
the detection of latent TB, complicated by the fact that patients lack clinical symptoms of the disease. 
To circumvent this, assays to detect the immune response elicited by the body upon exposure are 
currently under evaluation. The main tests to be developed for this purpose include the tuberculin skin 
test (TST), interferon gamma release assays (IGRA), which use a purified protein derivative (PPD) 
and early secretory antigen target 6 (ESAT-6); and culture filtrate protein respectively 
94
. 
Unfortunately TST also detects exposure to non-tuberculosis-mycobacterium (NTM) together with 
Bacillus Calmette–Guérin (BCG) vaccinations, whilst IGRAs offer superior specificity but are unable 
to differentiate between latent and active TB disease 
95
. NTM are Mycobacterium species, which are 
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not part of the M.tuberculosis complex, and examples include M.kansasii, M.avium, M.marinum and 
M.intracelulare to name a few. This group is of mycobacteria is responsible for a number of diseases 
such as pulmonary tuberculosis in HIV positive individuals 
96
. 
Active TB disease is primarily  detected using SSM, with a very heavy usage in areas with high TB 
incidence as it is quite rapid and simple 
91
. This has relegated the immune based approaches to a 





trained personnel and lacks any quality assurance measures to validate findings 
97
. Requiring multiple 
samples on separate days impart a heavy transport cost and potential loss of wages on the patient. This 
has led to a high number of patients missing the testing and subsequent treatment. The healthcare 
personnel performing SSM are limited to sixty seconds per slide due to the high demand of the test. 
The poor sensitivity for extra pulmonary, child  and HIV positive TB cases serves to further hamper 
the test  
98
. However, efforts are currently being evaluated to improve the performance of this test by 
use of light emitting diodes (LED) to perform fluorescence microscopy on sputum samples 
99
. This 
improves the speed of test and the visual clarity of the bacilli to the extent that increases in sensitivity 
of 10% have been reported 
100
.  
To help clinicians confirm TB disease, they perform chest examinations . Chest examinations are 
more applicable in cases of pulmonary TB, though a positive reading is not indicative of  TB disease. 
It uses the appearance of lesions in the lungs especially in the lower lobe as indication of disease. It 
serves primarily as an indicator of disease, but it is not truly a TB diagnostic 
91
. In a study detecting 
mediastinal lymphadenopathy (a TB hallmark in child TB), chest X-rays were found to detect TB 
cases in 67% of the cases 
101
. Imaging methods possess a nontrivial value in TB diagnosis but 
standardized disease rating and quality assurance measures are critical to amplify its clinical impact 
102
. The discussed approaches are indispensable for national TB control programs as they are the first 
line detection tools in high disease burden countries. Unfortunately, none of these is useful in 
measuring the drug susceptibility of the tuberculosis  detected. 
1.3.2 Drug susceptibility testing (DST) 
DST can be loosely classified as the monitoring of growth related metabolic activity of the 
Mycobacterium tuberculosis in the presence of drug or  detection of  mutations within the genome of 
the pathogen that are associated with drug resistance 
103
. The former  uses  culture-based methods 
whilst the latter relies on molecular assays. To ensure accurate execution, several parameters are 
routinely in application to measure their clinical performance. Two parameters that are constantly 
mentioned in the literature, are the sensitivity and the specificity estimates of the diagnostic tool 
104
. 
Sensitivity is defined as the probability of the tool correctly identifying a person with the tuberculosis 
disease 
105
. This  implies that a test with poor sensitivity yields a large percentage of false positive 





Specificity is the probability of the diagnostic tool correctly detecting an individual who does not 
harbour tuberculosis disease 
107
. A test with poor specificity produces an increased proportion of false 
positive results. Specificity is thus used to rule out the possibility of the disease for the patient 
106
. It is 
imperative for any diagnostic tool to have sensitivity and specificity estimates closer to 100%, but this 
is seldom the case. In spite of their usefulness,  cautious interpretations of their meaning is a 
prerequisite. The levels of disease incidence in the population were pilot trials are done should be 




Culture methods offer the capability of detecting actively metabolising M.tuberculosis at an increased 
sensitivity in comparison to SSM, coupled to the assessment of the bacterial viability in  the presence 
of drugs 
91
. It can be performed on various platforms such as solid media, examples including  
Lowstein-Jensen(LJ) media, utilized to do the proportion and resistance tests within periods of up to 4 
to 8 weeks 
109
. Such a wait period is too long for the diagnosis of this infectious disease, leading to the 
development of liquid culture systems. Prominent examples of the liquid cultures include BACTEC 
960 TB and the mycobacteria growth indicator tubes (MGIT). The BACTEC system detects 
radioactive carbon dioxide released from the metabolic activity of the M.tuberculosis on the palmitic 
acid substrate combined with NAP (β-Nitro Alpha acetyl amine β-hydroxyl propiophenone). NAP  
distinguishes M.tuberculosis from NTM. This test takes  5 to 10 days to yield DST results from 
patient samples 
110
. MGIT detects the growth of TB cultured in specific and differential media by 
using fluorochromes whilst performing DST within 7 to 12 days 
111
. These two tests have improved 
the testing of TB immensely but are prone to contamination, require well-maintained facilities, regular 
servicing and trained personnel. These requirements limit their applicability to highly centralized 
laboratories. A variant of liquid cultures is the microscopic-observation drug susceptibility (MODS) 
for TB 
112
. Using an inverted microscope, characteristic TB growth patterns (cords and tangles) can be 
easily observed facilitating simultaneous detection of TB and drug sensitivity directly from sputum 
samples 
112
. In a study by Moore et al  MODS was compared to  liquid culture and LJ culture systems, 
sensitivities of 97.8, 89 and 84% were obtained in 7, 22 and 68 days respectively 
112
. Other culture-
based tests are either in their infancy or under evaluation such that their impact is still to be 
established. 
Significant improvement in TB detection is observed when nucleic acid amplification (NAA) based 
molecular techniques are used in case finding. These are typically hinged on the polymerase chain 
reaction (PCR)  
113
. Examples of such techniques include the Amplified Mycobacterium tuberculosis 
direct  (AMTD) test from Gene Probe and Amplicor from Roche diagnostics 
114
. These tests detect the 
16S derived nucleotides amplified from highly specific primers by making use of DNA probes 
115
 and 
a colorimetric assay 
116
 respectively. These tests perform optimally with smear positive samples, but 
specificity and sensitivity diminishes when applied to smear negative samples. Another example of 
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the NAA is the Loop Mediated Isothermal Amplification (LAMP) test, a cheap method which does 
not require the often expensive thermo-cycling and detection devices associated with amplification 
assays 
117
. It has been successfully used to detect TB using specific amplicons such as the 16S rNA 
and hspX  
118
, successfully distinguishing M.tuberculosis from several species of NTM. Unfortunately, 
in spite of high sensitivity and specificity levels observed when testing sputum positive culture 
positive samples, the test has a diminished sensitivity of 48.8% for smear negative culture positive 
cases
119
. All the discussed molecular tools only ascertain the presence strains in the Mycobacterium 
tuberculosis complex, but the rise of MDR and XDR-TB cases worldwide has shifted the emphasis 
towards rapidly obtaining a drug susceptibility profile for the detected pathogen. 
Currently, culture based systems are the gold standard for DST but impressive inroads made by 
molecular DSTs will likely lead to its widespread use and ultimately replacement of culture methods. 
An example of a molecular DST is the line probe assays  MTBDRplusassay 
120
. It is a DNA strip 
based test which combines PCR with reverse hybridization techniques to detect mutations associated 
with rifampin (rpoB) and isoniazid (katG ,inhA) resistance 
121
. This assay has a modest turnaround of 
up to 48 hours from sample processing 
120
. In a study by Huyen et al, the sensitivity of this test was 
found to be 93.1% rifampin  and 92.6% isoniazid  with 100% specificity testing cultured isolated
122
. 
However, this assay still shows a very low sensitivity when used to assess clinical samples
123
. This 
test needs to expand the range of mutations detected to encompass other drugs and thus still requires 
confirmation of results as samples showing wild type profiles have been reported to harbour 
resistance phenotypes. Such instances can be as a result of epigenetic factors modulating drug 
susceptibility but mechanism are yet to be fully elucidated 
124
. It is also confounded by presence of 
NTM in the sample
125
.  
To date, the most revolutionary molecular DST tool has been the Gene Xpert system performing the 
Xpert MTB/RIF assay created by Cepheid 
126
. It allows the processing of the patient sample combined 
with a hemi nested PCR analysis in a largely hands free TB assay and rifampicin resistance detection 
simultaneously 
127
. It relies on a PCR assay that is based on molecular beacon technology, designed to 
be complementary to the wild type rpoB sequence
128
. Molecular beacons are hair pin shaped 
oligonucleotides (22-44bp) that are designed to bind to a specific amplified sequence by utilizing two 
fluorescent dyes that use fluorescence resonance energy transfer (FRET) 
113
 to produce a signal. FRET 
occurs when the two dyes overlap which is the case when they are spatially close together. When the 
beacon binds to its target sequence, the reporter and quencher dye are separated as the loop unravels 
which leads to fluorescence being detected
129
. Mutations in the rpoB region have also been reported in 
most  instances to be strongly suggestive of MDR-TB 
130
. The integration of sample processing, 
pathogen detection plus an electronic TB register (patient results automatically updated onto a cloud)  
within a self-containing module has made this tool a practical alternative with minimal risk to 
personnel 
130





study by Rath et al  projected that this assay will likely increase case detection by 37% but also 
increase the cost to the health care systems by about 55% 
131
. The assay has been reported to perform 
optimally with smear positive TB cases with 100% sensitivity, which diminishes when applied to 
smear negative samples to 68.6% sensitivity in an study which evaluated samples from 429 patients 
127
. The same was observed in a study comparing the performance of this device with MODS for 
smear negative samples from HIV positive patients 
132
. The MODS showed a higher sensitivity of 
73% compared to the 67% of the Gene Xpert device.  Interpretation of these findings is tempered with 
the realisation that  the variability of these readings could very well been a function of the setting and 
context of this particular study.  Irrespective of the impact this tool has made,  many limitations are 
diminishing its impact. It can only be used in areas with a regular electricity supply 
133
, requires 
constant availing of single use cartridges with a limited shelf life, needs specific humidity and 
temperature settings for optimal performance, is operated by trained personnel, requires annual 
servicing and calibration
134
. It has a limit of detection of 131 cfu/ ml 
135
 ,cfu being colony forming 
units. The Xpert device can only detect the presence of a mutant of TB if it has an abundance above 
65% in a mixed sample with the susceptible strain
130
. This implies that this device will struggle to 
detect heteroresistance.  
 At this moment, it still has intermediate sensitivity, greater than smear test but lower than culture, 
meaning that it cannot be used to rule out the disease due to false negatives 
136
. Unless the science 
behind this assay is reinvented, ambiguity will always be a confounding factor as rapid amplification 
of specific loci is an  imperfect proxy for slow but effective growing of M.tuberculosis 
137
. A 
significant fraction of patients that receive this test still require access to culture facilities, especially  
for sputum negative samples 
138
. 
1.3.3 Tests currently in the testing phase 
Several TB tests are currently in the diagnostic pipeline,  example being the breathalyser TB screen, 
developed by Rapid Biosensor systems 
139
. It comprises an easily portable device, which fits a 
disposable sample collection vessel. Followed by pneumatic transfer of the sample to a reaction centre 
primed with antibodies for the M.tuberculosis specific Ag85B antigen. These antibodies fluoresce 
upon binding to the target within 10 minutes. McNerney reported that 93% of TB culture confirmed 
cases accurately detected, but the assay was alarmingly susceptible false positive readings. Another 
variant of the TB breathalyser tests was reported by Jassal et a l
140
. This test detected the degradation 
of radioactive urea via the urease enzyme within 15 minutes. This technology has decent potential but 
further evaluation is critical for assimilation into TB control programs.  
A more promising point of care tuberculosis immunoassay is the lipoarabinomannan (LAM) detection 
in urine samples 
141
. LAM is a critical component of the mycobacterial cell wall, which can be 
detected using enzyme linked immunosorbent assays (ELISA). It is favourable sample as acquisition 
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noninvasively, possessing a reduced risk as opposed to sputum or blood samples. LAM is heat stable 
and therefore can be detected even after boiling the sample, making it a semi-quantitative TB assay 
with a 30 minutes turnaround 
142
. In spite of a low sensitivity of 56%, this assay was reported to 
outperform smear  microscopy in the case of HIV positive patients, suggesting its use as an additional 
initial test in the TB diagnosis algorithm 
143
. This test has a lot of potential because it is not affected 
by previous BCG vaccination and the diagnosis is thought  to be independent of the anatomical 
location of the disease 
144
. High rates of variability when applied in the field and the inherent low 
sensitivity are hindering further development of this test, but improvements are on-going 
145
. Another 
promising assay is the TB Patch test, based on the detection of the M.tuberculosis complex specific 
mpb 64 antigen. The assay showed  100% specificity to TB with a sensitivity of 98.1% 
146
 but it takes 
4 days to complete. However, it is very simple, unaffected by prior BCG vaccination such that if 
incorporated with a plethora of other antigens such ESAT6, HspX etc, it could be the basis of highly 
useful test in resource constrained areas 
147
. In a very different application, a TB patch was used to 
detect patient sensitivity to second line TB, suggesting that understanding and correctly adapting this 
technique can potentially lead to a much needed revamp of the TB control efforts 
148
. 
A variant of the phenotypic TB drug susceptibility is the bacteriophage-based assay. When viral 
particles infect M.tuberculosis, they replicate within the host eventually releasing the progeny post the 
virucide treatment. The release of the progeny is detected as either a plaque on a lawn of fast growing 
bacteria or by use of specially modified luciferase reporter phages 
149
. A positive result suggests drug 
tolerance whilst a negative result shows drug susceptibility of TB. An example of a commercial 
version of this assay is the FASTPlaque-MDRi 
150
. A novel device which detected the presence of the 
phage using  a piezoelectric sensor was reported to have sensitivity and specificity of 91% and 93% 
respectively 
151
 in 24 hours. An improvement on the specificity on the phages can make this assay 
more lucrative. 
1.3.4 High Resolution Melting Analysis: a potential TB diagnostic 
High Resolution Melting Analysis (HRMA) is a post PCR  method used to probe amplicons for 
sequence deviations such as single nucleotide polymorphisms (SNPs), mutations and DNA 
methylations 
152
. HRMA allows discrimination of PCR amplicons based on their size, GC content and 
complementarities 
153
. The method was introduced in 2002 by Carl Witter and Karl Voelkerding 
supported by Idaho technologies, whilst conducting research at the University of Utah 
154
. It exploits 
the fundamental ability of  DNA to denature when exposed to an ascending temperature gradient 
(0.008-0.2°C increments), melting at a specific temperature (Tm) reproducibly 
155
.  The Tm is the 
state in which half of the total DNA is single stranded whilst the other half remains double stranded. 
Short amplicons (<300bp) are better suited for analysis as they tend to melt with defined  singular 
peak as opposed to the multiple peaks observed with longer amplicons  
156
, thus they are normally 
selected for analysis. This was highlighted when a 544bp product from the human HTR2A gene 
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coding for production of the neurotransmitter serotonin was subjected to HRMA 
154
. The resulting 
profile showed two melt domains or peaks, making it difficult to identify the peak due to the single 
nucleotide polymorphisms. The fluorescence is measured by using DNA intercalating dyes such as 
LC Green, SYBR and Eva Green 
157
. The fluorescence readings at each temperature increment are 
passed through data processing steps such normalization and temperature shifting to produce melt 
curves and difference plots, from which the variations are easily observed 
158
. Several instruments 
currently perform HRMA including Rotor-Gene 6000, Light Cycler 480, Light Scanner and the 
Master Cycler.  
The application of HRMA  in tuberculosis studies has been mainly for detection of mutations  linked 
to drug resistance inadvertently to the first line drugs. It is accurate, cheap and simple to perform thus 
is very appealing  for diagnosis
159
. It is useful in identification and drug susceptibility testing in a 
number of studies 
159-164
. Rifampin resistance has been suggested as a high probability marker for 
MDR TB, thus HRMA could be a feasible alternative for drug resistance surveillance systems 
165
. In 
the same study, HRMA showed a very high positive likelihood ratio (PLR) and a low negative 
likelihood ratio (NLR), suggesting that the test can be trusted in ruling in or out cases of rifampin 
resistance. The test takes about 4 hours to complete, whereas culture based methods can take between 
4 to 8 weeks to identify and detect M.tuberculosis
166
. By switching the primer sets and reaction 
conditions, HRMA can easily be expanded to test for isoniazid, fluoroquinolone and streptomycin 












Table 2: Description of key studies analysed for the review of HRMA as a TB diagnostic. 
Table 2 above shows a brief analysis of studies on HRMA DST in tuberculosis from 2008 to 2014. HRMA has 
been successful in detecting resistance in a wide range of loci with very high analytical performance, shown by 
the various sensitivity and specificity estimates. A wide range of dyes, instruments and resistance reference 
methods have been used in the studies. 
Despite the advantages offered by HRMA, there are still a couple of challenges, which require 
addressing before this technique integrates into the clinical setting. There is need to improve the yield, 
purity and quantity of DNA obtained from the crude extraction methods used for clinical samples as 
Year Ref method Dye Genes 
studied 
Sensitivity% Specificity% Instrument Samples(n) Ref 
2008 Proportion 
method 











Resolight rpoB 95.9 100 LightCycler480 68 164 


















































































this greatly affects the assay
165
. For HRMA to be assimilated as diagnostic assay for M.tuberculosis, 
there is a need for establishing a modus operandi (which serves to standardize the instrumentation, 
reagents, DNA samples etc.) making it applicable at a global scale. During this assay, the intercalating 
dye binds to any dsDNA including chimera/ nonspecific PCR products leading to an overestimation 
of the PCR product
169
. This challenge can be addressed by use of hydrolysis probes such as 
(molecular beacons, taqman probes, scorpion probes etc.) which are designed to hybridize with a 
specific PCR product
113
. Incorporation of these probes unfortunately complicates the product 
detection, whilst increasing the cost of the assay. HRMA suffers from the same fate that all molecular 
diagnostics do, which is the inability to detect mutations outside the classified resistance determining 
regions. 
1.3.5 The Ultimate TB test 
The best TB test is one with very high sensitivity and specificity, with the ability to assay for drug 
resistance during the patient-health care worker contact events 
170
. It should be easy to implement at 
any level of the health care system with equal performance in children and HIV positive sputum 
negative individuals 
92
. This will effectively mean not requiring a steady supply of electricity, 
refrigeration or water without the need for trained personnel. The cost should be low enough for the 
test to be affordable by the underprivileged but the device should be able to detect the disease in the 
earlier stages. From these requirements, it is evident that the likelihood of finding such an assay is 
very low. The new diagnostic needs to have a minimum of 85% sensitivity and 97% specificity for it 
to make any meaningful impact as measured by the adjusted lives saved 
92
.The ultimate TB diagnostic 
should  be able to rapidly identify TB, test for drug susceptibility and determine the particular 
genotype of the strain for epidemiological studies. 
The success of any TB diagnostic is beyond the technology, but more a function of applicability and 
accessibility but this requires well designed studies with a proper appreciation of the ground 
conditions affecting patients and the entire health care system. Intensive operations and health 
delivery research is required  to understand how best to implement the new diagnostic 
91
. Instead of 
focussing on low prices for new tests, perhaps emphasis on subsidising the operational costs of 
existing tools, especially for high disease burden countries is a necessity.  
Before development of the ultimate diagnostic, exhaustive efforts are required to maximize the 
potential of current methods by  tailoring each solution for particular TB hotspots. For advantageous  
patient outcomes to be realised, a synergistic approach in discovery of the diagnosis tools, drugs and 
the health care delivery systems is of the essence. This should ideally be coupled with the eradication 
of socioeconomic triggers of TB disease which encourage the vicious disease and poverty continuum 
171
.  Addressing these issues is as important as  the discovery of the ultimate TB test 
172
, leading to a 
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comprehensive solution. From this passage, it is clear that TB diagnosis solutions will need to take 
advantage of latest technological advancements in a manner designed for the resource limited settings.  
1.4 Microfluidics and applications in Tuberculosis disease 
From the preceding section, it is clear that rapid, accurate technology and cost effective technologies 
are key in tailoring diagnostic tests for resource constrained high TB burden countries. Microfluidics 
offers a realistic alternative to solve most if not all of the functional and operational impediments on 
the current methods. Microfluidics use of minute volumes, in  highly integrated systems with 
improved sensitivity from their bulk equivalents 
173
. The aim of the following passage is to provide a 
succinct exposé to the microfluidic platforms and highlight their potential impact in discovery science 
and applied research with respect to tuberculosis diagnosis. Preference is given to PCR-based 
techniques as NAA are currently the most rapid tests in TB diagnosis.  
1.4.1The Microfluidics platform 
Microfluidics is defined as the science involved in the formulation and  production of devices that are 
capable of manipulating  minute quantities of samples or reagents (mostly in the order of nano litres) 
in a highly integrated manner 
174
. Microfluidics allows sample preparation and detection steps to be 
easily combined in extensively automated devices with high sensitivity, shorter reaction times and 
smaller device footprints in comparison 
175
. Whitesides  speculated that the advent microfluidic 
technology was a result of critical developments and requirements in four seemingly unrelated areas 
176
 . Development of molecular analytical tools such high-pressure liquid chromatography; combined 
sample separation and high-resolution detection were critical catalysts. Advancement in micro 
analytical methods especially during the rapid development of the genomics field about two decades 
ago hastened the need for devices capable of performing a high number of parallel reactions with high 
precision and accuracy. The third proponent of microfluidic technology was the need for devices that 
could detect small quantities of substances implicated in biological and chemical attacks post the cold 
war. The final driver of microfluidics came from methodologies successful in  microelectronics, as 
they proved to be easily transferable to microfluidics in creating biological circuitry. The 
combinatorial effect of the rapid developments in these fields formed the bedrock of microfluidic 
technology.  
The miniaturized experimental platform afforded by microfluidics allows for conservation of the 
biological sample and often costly reagents 
177
. Small volumes then translate into diminished thermal 
masses, increasing the heating and cooling rates of the reaction mixtures, a critical requirement for 
PCR 
178
. The mixing dynamics  improved at this scale. Hansen et al  showed that microfluidic systems 
could be used to significantly improve protein crystallization using free interfacial energy  by 
deciphering more conditions necessary for optimal reaction kinetics 
179
. The ability to perform 
identical reactions many fold helps to improve the statistical significance of the measurements. The 
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closed system minimises sample contamination and leakage, making it appropriate for application in 
clinical settings.  
Microfluidic technology has immensely benefited from advances in fabrication methods and materials 
used to create these devices, but it is yet to be fully integrated into mainstream biology 
180
. The major 
reason for developing this technology is to replace the existing methods by outperforming them, but 
in most cases, this has come at the cost of application specific devices, which are not readily usable by 
the average scientist. It is encouraging to note that recently, there has been an increase in collaborative 
efforts between engineers developing these tools and biologist with a finer appreciation of the end 
user necessities. This has led to the production of applicable and reliable devices based on solid 
scientific considerations 
181
. Such efforts are poised to yield devices that are efficient at performing 
the desired task whilst being easy to produce at a large enough scale for integration into research and 
commercial settings 
176
. These factors will likely propel the application of this technology into 
extensive use in TB diagnosis and research. 
1.4.2 Materials used for device fabrication 
Substrates used for the production of microfluidic devices have rapidly changed from the inception of 
this technology. Initial devices were produced  from  silicon , a direct consequence of using clean 
room fabrication techniques from the semiconductor chip industry 
180
. Silicon has very high thermal 
and electrical conductivity, making it easy to integrate micro-sensors and heaters. However, silicon is 
opaque, preventing optical detection, is brittle and inhibitory to biological processes especially (PCR) 
182
. The use of glass circumvented the opacity of silicon as it had been properly characterized 
183
. The 
same with silicon, glass chip fabrication is too expensive to allow production of disposable units 
182
, a 
critical part for low cost diagnostics. This prompted development of alternative materials. 
In light of the shortcomings of these entry-level substrates, elastomeric microfluidics are under 
development. Polydimethylsiloxane (PDMS), has emerged as promising material as its adoption has 
led to the unprecedented development of soft lithographic techniques 
180
. PDMS is a highly 
transparent, permeable and flexible polymer, with  reduced costs of production and superior 
biocompatibility with in comparison to silicon and glass 
182
. The elasticity of the PDMS can be 
exploited to incorporate micro pumps, valves and mixers 
184
. However, PDMS is incompatible with 
nonpolar solvents due to its hydrophobic nature ,which increases its permeability leading to  loss of 
biological material 
182
. This is a bio-hazardous challenge in clinical settings. Regehr et al  have shown 
that uncured PDMS can leach into the reaction mixture, affecting the observations during cell culture 
experimentation 
185
. It has been suggested that the hydrophobicity of PDMS  leads to the adsorption of 
small non-polar molecules, limiting use of this material in non-aqueous chemistry based processes 
186
. 
West et al  used a hybrid of  this polymeric material with silicon in order to exploit advantages offered 
by both materials, with moderate success in demonstrating the PCR reaction 
187
.  Due to several 
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application specific  modifications made to PDMS based devices cited in the literature, large scale 
production for commercialization is going to be challenging 
188
. 
The limitations of PDMS have compelled researchers to explore additional materials, including  
thermoplastics  such as polystyrene, a cyclic olefin copolymer 
180
, polymethyl methacrylate 
189
 , and 
polycarbonate 
190
. Use of these materials circumvents some of the drawbacks of PDMS including 
adsorption and evaporative loss, but production methods are still limited. Other materials that have 
been explored include paper, wax and cloth, preferred because they are low cost and easily destroyed 
typically by incineration, a necessity in low resource settings 
180
.  
The consensus is that more research is required in developing materials that address the scalability 
and compatibility issues. The solution will likely be a combination of various materials directed 
towards specific applications as opposed to trying to adapt a single substrate to various biological and 
diagnostic assays. However, it should be noted that new substrates will likely lead to an overhaul in 
the current device designs and fabrication methods 
180
. 
1.4.3 Temperature control and measurement systems 
Microfluidic technology allows integration of several functionalities, which ideally  allow the “sample 
in answer out” work flow 
191
. Key to facilitating this integration is the ability to exert a high degree of 
control on the various reaction parameters. Of the several parameters, temperature and fluidic controls 
are critical for devices performing the PCR reaction. This section highlights these two parameters, 
condensing the major variations on the theme found in the literature. 
Heating methods are critical in microfluidics as they are of importance in attaining desired 
temperature thresholds rapidly. The choice of method employed will depend mainly upon the 
temperature ramp rates required, which are critical in reducing the reaction time. Heating methods  
can be classified as either contact or non-contact methods
182
. Contact heating entails   direct physical 
fastening of the microfluidic device to the element supplying the heat. This contact can be established 
by using a thin film element embedded in the microfluidic device 
192
 or a heating block 
193
, with the 
latter limited by increased power consumption, slower ramp rates due to the larger thermal mass.  
Heating blocks tend to exhibit a higher degree of temperature spatial variation, but this can be 
addressed by using an oxygen free copper wafer as reported by Erill et al 
194
. There is a need to 
develop much improved contact heating methods which  allow differential heating of specific 
locations on chip, but these can have a negative effect on the ubiquitous nature of chip design 
195
. The 
microfluidic platform that will be discussed in the methodology sections utilizes the contact heating 
method. 
In an advanced variation of contact heating, thin metal film heat supply elements can be used for 
temperature control 
196
. These are characterized with higher thermal efficiency and consume less 
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power than heating blocks, whilst being easy to fabricate, pivotal for portable modules 
197
. Daniel et al 
198
 showed that a microfluidic device with a platinum based thin film heater rapidly amplified a 260bp 
product 
199
. However, these films are dogged by high costs and spatial variations that compromise 
accurate control of the thermal state of the system 
200
.  Inherent limitations of the contact methods 
have prompted experimenters to devise non-contact alternatives of heat supply.  
Non-contact heating involves temperature cycling of the microfluidic device without physical contact 
with the heat-supplying unit, greatly diminishing the thermal mass of the process setup. Such a 
configuration is advantageous in terms of integration with  down- and upstream processes in the 
reaction 
201
. Some of the earlier work on these types of heaters involved differentially heated streams 
of air, with very high ramp rates 
202
. Other non-contact methods rely mainly on the absorption of 
electromagnetic radiation (EMR) by the device, mainly optical radiation (infra-red) and microwave 
radiation 
203
. Infra-Red heating uses a tungsten lamp that has been shown to produce detectable 
quantities of a 800bp product in 240s 
204
. In spite of this, lamp based heating yields non-focussed 
light, which reduces the efficiency of the overall process. To circumvent this issue, researchers have 
developed laser based heating methods, with ultra-fast ramp rates 
205
, but require precise positioning 
of the reactor and the light source. Microwave heating has proved to be very useful in PCR reactions, 
with an almost instantaneous temperature response ,whilst being easy to focus on reaction mixture  
201
. 
Another variant of the non-contact heaters is induction heating, which  involves placing the 
microfluidic device in close proximity to a heated element monitored and regulated by a programmed 
temperature control loop 
201
. This method has been shown to require less complicated fabrication 
techniques and achieve fast temperature transition rates 
206
. 
Temperature measurement is as important as temperature control in PCR, serving as feedback for the 
control system. Following on  the previous theme, temperature measurement systems divide into 
contact and non-contact methods. Contact based measuring devices include thin film sensors, 
thermocouples and electrical resistance heaters 
201
. The larger the temperature-measuring device, the 
more there is an undesirable increase of the thermal mass of the system. This is true for the 
thermocouples and the resistance heaters. These methods measure the temperature at a discrete 
location on the chip, compromising the accuracy of the measurement, as they cannot infer on chip 
spatial variation of the temperature. In spite of these drawbacks, these methods are popular as they are 
easy to install and use.  The thin film sensors are an attempt to circumvent some of these limitations. 
They have been increasingly applied as developments in thin film deposition techniques are occurring 
207
. Non-contact sensors of temperature offer the ability of measuring the temperature with no physical 
interference with the sample, obtaining a more realistic depiction of the thermal state of the system 
rapidly. An example of such a sensor is  infra-red (IR) thermometry, which uses the emission 
thermograph to determine the temperature after appropriate calibration 
182
. In spite of these 
advantages, environmental factors such as the background noise, chip emission characteristics 
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diminish performance of the IR sensor. IR only measures surface temperature readings. Some 
researchers have proposed the use of thermo-chromic liquid Crystals  (TLC) to measure temperature 
208
. These molecules have liquid-like mechanical properties whilst retaining the optical behaviour 
typifying solid substances and they readily respond to variation in temperature. They are still to be 
properly converted to the actual functioning forms as studies on them are still on-going 
209
. 
1.4.4 Fluid transport 
This section provides a brief overview of the fluidic handling capabilities of the microfluidic platform. 
It is in no way exhaustive but rather a small window into the colossal arena of fluid flow within the 
microfluidic devices. 
One of the pioneering fluid transport mechanisms is the lateral flow. Based on capillary action, this 
form of fluid migration  is dependent on the absorptive properties of the  substrate
210
. In such tests, the 
operation is typically simplistic, with a sample loading area and result detection window. To date, this 
method has been demonstrated to perform best with immuno-based assays which can detect the 
presence of specific antigens from several samples by combining several loading, reaction, and 
detection steps in a simple flow-through process which typically takes a couple of minutes 
211
. In spite 
of being easy to implement, the simplicity of the platform means it is very difficult to have high 
precision liquid control, limiting the amount of different operations that can be performed on such 
platforms 
212
. Another form of fluidic movement is linear actuation, in which the liquid is moved via 
mechanical displacement 
213
. Devices using this type of system have loosely connected cavities or 
channels, for single use reactions. They are easy to calibrate using internal controls. As with the 
lateral flow systems, complex assays are difficult because of imprecise control. Another variation of 
fluidic transport involves the use of pressure driven laminar flow of the fluid streams
214
.This is 
achieved by establishing differential hydrodynamic gradients with the flow routes 
210
, which facilitates 
the implementation  syringes, pumps, micro pumps etc. This methodology allows predictable 
velocities to be established in the channels with biphasic flow streams
215
, with very accurate focussing 
of micro particles. The requirement for pressure sources complicates the portability of devices using 
this form of fluid actuation, together with the taylor dispersion of fluid streams potentially altering the 
concentration of the reagents in longer sample routes
216





 and electro kinetics 
219
, each with their own strengths and 
limitations. This review will not discuss these in detail, as application  in microfluidics research is still 
limited.   
Perhaps the most revolutionary fluid flow technique has been the microfluidic large scale integration 
(MLSI) system, which was first reported in 1993
220
. A layer of fluid flow with another layer 
pneumatically controlling the fluid called the control layer guides the fluid flow. The combination of 





. This method requires simple soft lithographic fabrication to produce the masks and 
moulds used to produce the micro sized features on chip, with PDMS as the main substrate
221
.  The 
impact this technology was displayed when the Quake group developed multilayer soft lithographic 
techniques that enabled the binding of several flow and control layers
222
. The company Fluidigm in 
the USA, has championed the fabrication of these densely packed chips with complicated plumbing. 
Devices boasting such architecture are useful in various operations including DNA isolation, protein 
crystallization and immunoassays 
222-225
. In demonstration of the scale at which these devices operate, 
a 250pL sized microfluidic chip with 1000 individually addressed reactors with 3574 valves was 
reported 
226
. Microfluidic chips have been shown to be cheap and sturdy, together with being easily 
programmable either by the design of the actual circuitry or externally by preferential  addressing the 
individual valves 
210
. The only drawback with this technology is that PDMS is not compatible with 
organic solvents and there is a need for a pressure source for the control and flow layers which 
complicates the design of POC systems
227
. However, with adequate funding and intellectual resources, 
these challenges are amenable.  
1.4.5 Detection methods 
Microfluidic technology strives to miniaturize all aspects of their macroscopic counterparts, but this is 
only true for some aspects  as devices do not simply scale down that easily. Miniaturization provides 
improved analytical performance at lower reagent cost but this also means a reduction in the 
detectable analyte
228
. It is imperative for any sensing systems to balance sensitivity with the 
scalability. Several methods for detection have been developed which include electrochemical (EC), 
mechanical and optical detection methods
229
. Electrochemical sensing occurs when the progress of a 
reaction results in the release of an electric signal sensed using either an electrode or probe as shown 
in the work by Lee et al
230
. Unfortunately the reading is affected by variations such as temperature, 
pH and the ionic activity, limiting their applicability
229
. Micro-scale mechanical sensing systems, 
based on cantilever beam technology can be useful in diagnostic tests. The detection in such systems 
is done by either a static micro-sized module which alters its surface forces leading to a deviation of 
the cantilever beam
231
 or a resonant module in which analyte attachment leads to a deviation in 
frequency at which the beam resonates
232
. Unfortunately, the detection limits of these devices are 
constrained by the mechanical losses associated with the beams. As consequence of the current 
limitations of both EC and mechanical sensing, optical sensing methods are still more prevalent in 
microfluidic technologies.  
Optical detection is widely applicable in microfluidics as it allows the detection in a wide range of 
assays using absorbance, chemiluminescence and more so fluorescence. Light focusses on the chip 
using pinholes, and by combining this to photo multiplier tube (PMT) and closed circuit device 
(CCD) camera, low detection limits are realised. Absorbance by definition is the ratio between the 
incident and transmitted light through a material or solution
233
.It has been widely applied in detecting 
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analytes in large quantities but rarely used at a microfluidic scale. This a direct consequence of 
miniaturization, which significantly reduces the optical path from the light source to the detector, 
compromising the measurement
234
. A microfluidic chip which could measure the amount of ammonia 
was reported by Du et al
235
. The chip facilitated the indophenol reaction, detecting the product using a 
liquid core wave-guide spectrometer, obeying Beer-Lamberts Law in the range 1-100µM of the Fe
2+
 
calibrating solution. An integrated complementary metal oxide semiconductor (CMOS) imager  
bonded to a polystyrene microfluidic network was then used to measure the uric acid content in 
urine
234
. Currently there is no reported study, which used absorbance to detect PCR amplicons.  
Chemiluminescence (CL) occurs when a chemical reaction produces a highly unstable product that 
decomposes and releases energy in the form of light as it assumes a more stable resting state 
236
. The 
internal excitation of the analyte makes such reactions very attractive for use on the microfluidic 
platform as there is no need for a light source but is obviously limited to reagents which are able to 
emit light 
234
. A PDMS microfluidic device was used to detect the antioxidant capacity of different 
solutions using the peroxyoxalate (PO) assay where CL was used to detect the product in which the 
reagents were loaded by injection 
237
. Analytically, the assay performed very well and it showed 
potential for applications in the field. Unfortunately, a bulky inverted microscope was used for 
detection the product.  A device which resembled the monolithic strata was reported to perform the 
PO assay using thin film photodiodes to facilitate the micro-scale CL
238
. The device had very good 
analytical performance and a low reaction time of 11 minutes. Delaney et al reported a variation of 
CL in which the reaction was triggered by the application of an electric pulse to the reaction in what is 
known as Electrochemiluminescence (ECL) 
239
. This device was shown to be low cost (paper based), 
easy to manufacture (produced from an inkjet printer) and more importantly only required the camera 
from a standard cell phone for detection of NADH. ECL is yet to be shown to be capable of 
monitoring a PCR amplification process 
201
.  
Fluorescence occurs when a substance releases light after absorbing electromagnetic radiation (EMR) 
240
.The emitted light is always of a lower energy (higher wavelength) in comparison to the absorbed 
radiation. It the most widely used sensing system in microfluidic devices. Several excitation sources 
can be used which include lasers, xenon and argon lamps 
241,242
. Lasers tend to be easily miniaturized, 
producing EMR which is very coherent with low divergence, enabling them to easily focus on the 
chip and deliver high energy radiation 
234
.  Lamp based systems are significantly cheaper than lasers 
and also offer  a wide range of excitation wavelengths. Lamp based light sources have been largely 
used in microscope based detection modules with excellent results. Developments in the laser 
technology have been extended to the lamps leading to high energy stable lamps with increased 
wavelength range from ultraviolet to infrared with very long shelf lives 
242
. A  microfluidic device 
simultaneously detecting multiple fluorochromes was reported which used a halogen lamp 
243
. An 
alternative light source in fluorescence based systems is the light emitting diodes (LEDs), which 
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consume less power and are easy to integrate into micro-sensing systems 
244
. Fluorescence detection 
takes a central role in systems that perform PCR assays as virtually all detection dyes such as 
saturating dyes, probes; molecular beacons etc. are detected using fluorescence imaging. LEDs have 
been combined to smaller PMTs in a portable PCR device 
245
. In spite of its applicability, fluorescence 
detection is still limited by background signal especially when using components that auto fluoresce, 
coupled to their often prohibitive pricing 
229
.  
The brief exposé on the fundamental elements of microfluidics from substrates to detection highlight 
some of the basic considerations when fabricating these devices. A lot more work is required to 
miniaturize all the components. For all the functional elements of the chip from fluid movement to 
product detection, a compromise is necessary to produce robust and applicable devices. An efficient 
and consistent fabrication method for easy implementation of this technology in the life sciences is the 
missing link. If it could take a similar route as electronic chips, that is to have separate unit modules 
which can be combined for a very specific outcome, that would surely be a game changer 
210
. The 
following section discusses some of the publications that have reported the use of microfluidics in TB 
related research. 
1.4.6 Application of microfluidics in TB research 
The discussed advantages of microfluidics make it a very strong candidate in revolutionizing the way 
in which future diagnostics will operate. This is relevant because it allows diagnostics to be created 
that are more applicable to developing countries as opposed to the developed countries 
246
. Devices 
that have been applied so far in TB related research have been to detect either whole Mycobacterium, 
nucleic acids from M.tuberculosis or to measure the immune response from patients with TB 
247
. With 
no immunological reaction  unique to TB disease reported, an immuno-diagnostic is still elusive. This 
section sheds light on some of the research  applied in TB related work. Most of the devices to date 
have concentrated on the detection of M.tuberculosis whilst the exceptions extended the devices 
capabilities to detecting drug resistance. 
Ke et al reported in 2004 a microfluidic chip  amplifying and detecting amplicons from the rpoB 
region of M.tuberculosis 
248
. The device was fabricated using silicon, using a high power halogen 
lamp as the heat source. However, the amplicons were detected using gel electrophoresis, which is not 
applicable at the POC level. This is because electrophoresis only reveals information only about the 
size and not the sequence of the amplicon. Rosenfield  used the activity of the M.tuberculosis specific 
β-lactamase enzyme on a fluorogenic substrate to detect the presence of M.tuberculosis using droplet 
based microfluidics 
249
. The study was a proof of concept using E.coli for optimisation with a 
moderate rapidity of 150 minutes. It was reported by Xie et al that fluorogenic substrates could be 
used to detect and distinguish Mycobacterium tuberculosis complex from other environmental 
bacteria within 10 minutes 
250
 , using a LED excitation source with a very portable imaging unit. Gold 
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nanoparticles were shown to be very efficient in detecting M.tuberculosis amplicons from the 1S 6110 
loci on a paper based microfluidic chip 
251
.Optical detection was via a mobile phone camera with a 
reaction time of 1 hour. Unfortunately, amplification on a separate device with the product detection 
modules suggests the assay is not ready for deployment. The gold particles were further developed to 
detect mutations in the MTB genome linked to drug resistance in different study 
252
. A microfluidic 
device was coupled to a nuclear magnetic resonance (NMR) biosensor for the detection of 
M.tuberculosis 
253
, on the principle that binding of the biomarker alters the spin of the water 
molecules. The reaction time was 30 minutes using various samples from blood, saliva, sputum etc. 
with a detection limit of 20 cfu/ml. The detection module costs about 200 USD, whilst a single 
microfluidic cartridge costs one USD, which is very attractive for the emerging markets. 
A microfluidics platform for  M.tuberculosis strain genotyping was reported 
254
.Such a device will 
prove to be indispensable in monitoring outbreaks to discover and understand transmission events, 
adding precious value to the clinician- patient contact sessions. The chip used variable number 
tandems repeat (VNTR), which identifies TB strains by the number of mycobacterial interspersed 
repetitive units. Unfortunately, the entire process requires a long turn around and complex machinery 
limiting use to central laboratories 
255
. A microfludic device was used to confirm that exposure to 
bedaquilline causes M.tuberculosis to reorganise metabolism in the first 4 days 
256
. Using  time-lapse 
microscopy with GFP construct of the pathogen, the bacteria depressed consumption but increase 
production of ATP. Perhaps the most comprehensive application of microlfuidics in TB diagnosis was 
reported in the study by Phowlat  using a taqman Array Card (TAC) 
163
. The study documented an 
assay  capable of detecting mutations known to confer TB drug resistance using hydrolysis probes, 
simultaneously detecting unknown mutations using (HRMA). TAC accurately interrogated 10 
different genes linked with drug resistance. When applied to 230 clinical isolates, the assay had 
accuracies of 96.1% and 87% when compared with the Sanger and Culture based methods 
respectively. However, there was still need for a benchtop centrifuge to disperse samples amongst the 
384 wells. In addition, performing bulk PCR  means that the assay TAC struggle to detect 
heteroresistance. HRMA could not detect transversion mutations. 
Several authors have demonstrated the successful incorporation of microfluidics into the POC, 
offering superior functionality in comparison to conventional methods. This section showed the 
different facets that make up microfluidics, together with their application in the fight against TB. The 
current challenges  technology are solvable through a concerted multi-disciplinary towards this 
epidemic.  
1.4.7 Reality of TB diagnosis situation 
TB infects about 9 million people annually, whilst 2 million people die each year
257
. On average, an 
individual carrying the active and dispensable M.tuberculosis can infect around 15 individuals each 
29 
 
year if disease progression is not disrupted
258
. For the transmission of this highly infectious agent to 
be timely disrupted, the disease needs to be detected at a very early stage and appropriate treatment 
commenced as soon as the diagnosis is made
259
. The most accessible tool in high disease burden 
resource limited countries is sputum smear microscopy (SSM). SSM  only detects M.tuberculosis in 
50% of cases with diminished  sensitivity for children and HIV-positive individuals 
260
.An  increase in 
the case of drug resistant strains such as MDR, XDR and TDR-TB 
78
 at a global scale demands a 
higher level of information from the diagnosis, which is the drug susceptibility profile of 
M.tuberculosis strain. Thus, the replacement of SSM with a test applicable and accessible in  any 
primary health care facility is of paramount importance. 
1.4.8 Problem statement  
The current health care systems in developing countries cannot cope with the burden of 
M.tuberculosis diagnosis resulting in over 3 million cases being missed annually throughout the 
world
261
. The emergence of drug resistance forms of M.tuberculosis has only served to worsen the 
situation as now secondary information on drug susceptibility is a must for each positive diagnosis
262
. 
1.4.9 Research rationale  
There is a need to develop alternative diagnostic systems that  to detect M.tuberculosis and its 
accompanying drug susceptibility profile at a primary health care level in a cost effective manner. 
This is achievable through the development of a reliable, reproducible and rapid assay by exploiting 
the strengths of microfluidics and HRMA. 
 Aim 
 To develop a microfluidic based diagnostic tool to detect mutations that are  linked to drug resistant 
Mycobacterium tuberculosis. 
Objectives 
1. Develop and optimise a PCR based assay for detecting drug resistance using a conventional system 
2. Perform assays with isolates of M.tuberculosis using the microfluidic platform 
3. Evaluate performance of microfluidic platform using the laboratory strains of M.tuberculosis 






CHAPTER 2: METHODOLOGY 
This chapter documents the various methods used during the course of the study. Some 
M.tuberculosis strains are supplied as heat-killed cells. These will undergo the DNA extraction 
protocol summarised in a subsequent section. The purpose of this step is obtaining a pure sample with 
a high yield.  The DNA samples are directly applicable in the assay post evaluation of their purity and 
DNA concentration.  The phenotypic drug susceptibility of the test strains for use as a benchmark for 
the findings, accompanies the strains. The next section is detailing the primers selected for the assay. 
Primers carefully designed ensure efficient amplification of the product. The subsequent sections 
show the PCR master mix constituents for use on the Light Cycler96. A brief description of the 
Sanger sequencing reactions follows. Sanger sequencing allows accurate detection of single 
nucleotide polymorphisms within the various genes.  A segment on the succinct method used to 
design and produce the microfluidic device coupled to the reaction master mix and reaction profile 
conclude the chapter. 
2.1  M.tuberculosis test strains  
Two groups of Mycobacterium tuberculosis samples are available. The first group consists of H37Rv, 
R35, KZN 605 and R271, cultured at the Nelson R. Mandela School of Medicine (Durban, South 
Africa). These strains have known drug susceptibility phenotypes and genotypes as reported in a 
previous study 
7
. The second group consists of DNA from clinical isolates Tkk-062, Tkk-050, Tkk-
043 and Tkk-039 obtained from the KwaZulu-Natal Research Institute of Tuberculosis and HIV (K-
RITH), (Durban, South Africa), after proper characterization of the phenotypic drug susceptibility 
patterns. 
 DNA extraction 
The first group of MTB strains were supplied as heat killed samples and the DNA is extracted using 
the CTAB method as reported  
263
. In summary, the sample is mixed with 450µl of GTE buffer and 
50µl of 10mg/ml lysozyme (Sigma, Germany) with an overnight incubation at 37°C. 150µl of a 2:1 
mixture of SDS (Sigma, Germany) and 10mg/ml proteinase K (Sigma, Germany) is added with 40-
minute incubation at 55°C. This is followed by the addition of 200µl of 5M NaCl (Sigma, Germany) 
and 160µl of heated CTAB (Sigma, Germany) followed by a 65°C incubation for 10 minutes. 1ml of 
24:1 chloroform/isoamyl alcohol was added  to the samples, followed by centrifugation and removal 
of the top aqueous layer. This step was repeated and the extracts were recombined. 560µl of 
isopropanol (Capital Labs, South Africa) the extract with gentle mixing. A micro centrifugation step 
for 10 minutes followed. After discarding the supernatant, 70% ethanol was added to the pellet with 
mixing and another microcentrifugation step  for 10 minutes. The supernatant was discarded and the 
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air-dried pellet was then suspended in TE Buffer. The final DNA concentration of the extracts was 
determined using the Nano Drop Lite (Isogen, Netherlands) and the results are shown in the appendix. 
2.3  HRMA primer 
To detect mutations for rifampin, isoniazid and olfoxacin resistance primers corresponding to the 
resistance determining regions rpoB, (katG and mab-inhA) and gyrA were used. For rifampin 
resistance, rpoB primers amplify the 81bp region between codons 507 to 533, for katG the primers 
amplify the 315 site whilst the mab-inhA amplify the -8 and -15 sites, forming the basis for isoniazid 
resistance. The gyrA encompasses several sites associated with ofloxacin resistance. The primer 
information is summarised in table 3, as adapted from 
160
. 
2.4  Realtime PCR and HRMA 
The PCR Master Mix was prepared by adding 25µl of 2X Xtreme™ Buffer (Novagen, Toyobo), 10µl 
of dNTPs (Novagen, Toyobo), 5µl of LC Green (Idaho Technology Inc, Salt Lake City, UT), 0.3µM 
of each primer, 1µl of KOD Xtreme™ Hot Start DNA polymerase (Novagen, Toyobo) and 5µl of 
template DNA containing 200ng of the DNA  make a final volume of 50µl. PCR was performed using 
the Light Cycler96 (Roche Diagnostics, Switzerland). The initial denaturation temperature was 95°C 
for 300s, followed by 35 cycles of 95°C for 10s, 60°C for 10s, 72°C for 10s (fluorescence readout 
step). A non-template control (NTC) was included in all experiments, in which  distilled water was 
used instead off the DNA template. 
For the HRMA step, the following profile was used: 95°C for 60s, 40°C for 60s, 65°C for 1s then at a 
0.07°C/s ramp rate, acquiring 15 readings every degree until 97°C. Difference plots were generated  
using H37Rv as the baseline signal and then normalizing the test readings (all the other samples) with 
respect to this standard. 
2.5  DNA sequencing of rpoB, katG,gyrA and mab-inhA 
The PCR amplicons generated from rpoB, katG, mab-inhA and gyrA genes were sequenced by Inqaba 
Biotech Industries (Pretoria, South Africa) using the same primer sets used to produce them. In 
summary, the Sanger sequencing method was used post a clean-up step using the ZR-96 DNA 
Sequencing Clean-up Kit™ (D4052). The products were sequenced in both the forward and reverse 
directions using the Big Dye® Terminator v3.1 Cycle sequencing kit from Applied Biosystems 
(California, USA). The cleaned products were injected on the ABI3500XL analysers and the data was 
analysed using software at Inqaba Biotech Industries (Pretoria, South Africa). 
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2.6 Microfluidic realtime PCR 
2.61 Microfluidic device fabrication 
A co-partner on this project, Mr Tawanda Mandizvo, carried out the process of device fabrication. 
The device was produced in line with the principles of Microfluidics Large Scale Integration (MLSI),   
previously discussed 
226
. A succinct summary of the process is provided in the following paragraph. 
The initial step involved designing the control and flow layer of the 2 layer push up chip. This was 
followed by the production of the photomask and consequently the mould. The mould was used to 
replicate with high fealty the features on the design. The flow layer was a 5:1 mixture of PDMS and 
Part B (curing agent) and the control layer a 20:1 mixture of the same constituents. They were 
partially baked at 80°C separately for 30 minutes, carefully stacked with the control layer at the 
bottom (aligning with a stereomicroscope), and then bonded to a silicon wafer during an 8-10 hour 
final bake at 80°C.  
The Master Mix used for the on chip experiments was modified from the one used in phase 1 in order 
to compensate for the losses that occur when the chip is being loaded, an approach adopted  in  a 
previous study by 
264
. The PCR mixture was prepared using 30µl of 2X Xtreme™ Buffer (Novagen, 
Toyobo), 15µl of dNTPs (Novagen, Toyobo), 9µl of LC Green (Idaho Technology Inc, Salt Lake 
City, UT), 0.46µM of each primer (Life Technologies), 3µl of KOD Xtreme™ Hot Start DNA 
polymerase (Novagen, Toyobo), 0.08%(v/v) 1% Tween 20 and 3µl of template DNA with a total 
quantity ranging from containing 100ng to make a total volume of 75µl. For the 20 reactor chip, 8 
reactors were used for H37Rv, 8 for the test strains (R35, Kzn 605) and the other two reactors 
contained the non-template controls. For the the final experiment, 6 reactors contained H37Rv, 6 
contained Tkk-062, 2 contained non-template control reactions and the other 2 had an H37Rv reaction 
with gyrA primers as a positive control. 
The thermal cycling was performed using a modified G-STORM GS1 (Somerten, UK) thermocyler, 
measuring the fluorescence in real-time using an Olympus MVX10 (New York, USA) macroscope. 
The thermal profile was 99°C for 8 minutes, followed by 35 cycles of 99°C for 65s, 60°C for 115s, 
74.5°C for 130s, and 40°C for 90s, and 97°C for 120s. 
For the HRMA step, the temperature increased from 75°C to 94°C at a ramp rate of 0.5°C/s with 
0.25°C increments for each step. The real-time and HRMA steps on the chip were captured using the 
Light Forge software, which was developed in house by Dr Frederick Balagadde. The software is 
essentially temperature feedback system is capable of acquiring fluorescence readouts at easily 






Table 3: Information about the primer sets adapted from 
160
. The table above shows the primer sets 
that were used for the PCR and Sanger sequencing. The primers annealing temperatures ranged 
between 63 to 65°C, amplicon size between 118 to 233bp and GC content between 36 to 68.7%. The 
nucleotide positions are numbered relative to the transcriptional start position of each of the genes. 
The accession numbers for the sequences on the National Centre for Biotechnology Information 
(NCBI) site are provided. It is interesting to note that the annealing temperature in table 3 is higher 
than the 60°C used in the actual reactions.  










rpoB F CGCGATCAAGGAGTTCTTC 65 2339 to 2357 118 36 L27989.1 
rpoB R TGACAGACCGCCGGGCCC  2456 to 2439    
mab-
inhA F 
GTCACACCGACAAACGTCAC 64 100 to 119 
 
190 57.9 U66801.1 
mab-
inhA R 
CTCCGGTAACCAGGACTGAA  296 to 271 
 
   
katG F GCGGTCACACTTTCGGTAA 64 2781 to 2799 233 68.7 X68081.1 
katg  R GGTGTTCGTCCATACGACCT  2950 to 2931    
gyrA F GGTGCTCTATGCAATGTTCG 63 2467 to 2486 169 65.2 L27512.1 
gyrA R GCTTCGGTGTACCTCATCG  2700 to 2682    
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CHAPTER 3: RESULTS 
3.1 HRMA with Light Cycler96  
The following section documents the findings when the test strains were evaluated using the Light 
Cycler96 machine. A short description of the significance of each of the results is given. 
For each gene, a histogram documenting the average cycle threshold numbers (Cq) observed for each 
strain is given. A Cq number is essentially the number of cycles required for the fluorescent signal 
from each well to cross a particular reaction threshold. The threshold is typically located in the early 
exponential phase of the amplification process. For accurate HRMA, the amplification has to occur 
efficiently and reproducibly. Thus, for reactions  accumulating product at the same rate, the Cq value 
will more or less be the same 
265
. A threshold number less than 29 shows efficient amplification. The 
Cq value is only valid if the non-template control does not cross the threshold during the course of the 
reaction. It should be noted that Cq values are only comparable within the same run 
266
.  
A table showing the numerical measurements of the melting point temperature (Tm) for each gene 
follows. The findings in the table are normalized estimates melt curve data (not shown) transformed 
by generating a negative derivative to the give melt peaks. The melt peak data is fitted to the 
Savitzky-Golay 
267
 function automatically by the software to produce smoothened data. Emphasis is 
placed on the estimates of the standard deviation (stdev) and the standard error (sem) for each test 
strain. The standard deviation shows how variant are the observed Tm from the average Tm also 
shown in the table. It describes how spread the data is from the mean and an estimate many fold less 
than the mean whilst being closer to zero shows minimal variation in the Tm value. Another important 
parameter in the table is the standard error, which documents the reliability of the calculated average. 
For successful HRMA, these estimates will be more than 100 fold less than the calculated mean, 
whilst 68% of the observed Tm estimates should be within plus or minus one standard deviation 
268
. 
The technical specifications of the Light Cycler96 state that the replicates of the Tm measurement 
vary with 0.4°C. Thus the melting temperature alone, cannot be relied upon if the difference between 
the standard and test strains Tm is less than or equal to 0.4°C. 
A visual depiction of the replicated readings of the melting point temperatures follows the table. 
These are useful in clearly showing the deviation of the melting point temperatures of the test strains 
using H37Rv as the standard or susceptible strain. This graph is useful in distinguishing the variants 
from the reference strain. A test strain is called variant if its Tm values are not in the same horizontal 
region with H37Rv, whilst those located in different regions are classified as wild type or non-
mutated strains.  
The final graph used in the decision-making i.e determining whether a test strain is called variant or 
non-mutated is the difference plot, generated by subtracting the normalized fluorescence of the 
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reference strain from that of the test strain. The resultant figure depicts the different profiles showing 
the mutation controlled deviation of normalized melt curves. Some mutations tend to lead profiles 
above the standard or baseline, whilst other mutations are located below that of the reference. 
Mutations, which do not significantly alter the thermal denaturation profile such as class 3 and 4 
single nucleotide polymorphisms, will likely be very similar if not identical to the reference.  
Thus by individually and collectively analysing results from these plots and tables, a conclusion is 
reached on the drug susceptibility of each strain at the various loci. The accuracy of the assay is 
reported as percentage sensitivity, the probability of the assay detecting a strain with the mutation. 





















 3.1.1Rifampin resistance assay 
rpoB 
 
Figure 2: Cycle threshold (Cq) values for the laboratory M.tuberculosis at the rpoB loci. The diagram 
above shows the average Cycle threshold values for the rpoB amplification of replicates of the clinical samples. 
All the observed values were below 29 and the non-template control was negative, suggesting that the reaction 
was successful. Within this run, it is plausible to conclude that all the strains amplified efficiently enough to 









  H37Rv  R35 Kzn 605 R271 Tkk-050 Tkk-062 Tkk-043 Tkk-039 
88.69 88.99 89.4 88.51 88.44 88.8 88.52 88.5 
88.7 88.9 89.33 88.42 88.45 88.71 88.5 88.5 
88.75 88.9 89.3 88.36 88.43 88.78 88.51 88.44 
88.66 88.92 89.32 88.56 88.42 88.65 88.4 88.44 
88.77 88.86 89.34 88.48 88.42 88.73 88.42 88.46 
88.65 88.88 89.32 88.55 88.41 88.7 88.45 88.4 
88.76 89.01 89.29 88.48 88.4 88.69 88.45 88.4 
88.69 88.93 89.3 88.47   88.71 88.47   
Count 8 8 8 8 7 8 8 7 
Mean  88.71 88.92 89.33 88.48 88.42 88.72 88.47 88.45 
Stdev  0.046 0.052 0.035 0.066 0.017 0.049 0.043 0.041 
Sem  0.016 0.018 0.012 0.023 0.0065 0.017 0.015 0.016 
Table 4: Melting point temperatures of individual replicates for the laboratory strains at the rpoB. The 
table above shows the melting point temperatures obtained for each of the replicates for the different samples. 
Both estimates of the standard deviation and the standard error are smaller than the mean value whilst being 
closer to zero. On inspection, it is clear that at least 68% of the observed values are within one standard 
deviation of the mean, showing that the data is normally distributed. The data suggests that there is minimal 
variation with the observed readings and the differences in the average temperatures are a result of the 
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Figure 3: Visual depiction of the variation of the melting temperatures of the various strains at the rpoB 
region. Figure 3 depicts the variation in the melting point temperatures of the amplicons from the reactions 
involving different test strains and H37Rv. H37Rv and Tkk-062 were located in the same melting point 
temperature region. R271 and the remainder of the Tkk strains showed a melting point, which was lower than 
that of the standard H37Rv. R35 and Kzn 605 showed melting point temperatures that were elevated in 
comparison to the standard. The high degree of cluttering amongst the replicates follows on from the suggestion 





Figure 4: Difference plot showing the variation of the thermal dissociation profiles of the rpoB amplicons 
of the test M.tuberculosis strains. The figure above shows the different plots of the various amplicons, 
highlighting the profiling pattern in which each strain clustered into four different profiles. H37Rv and Tkk-062 
cluttered into the same class, the red baseline.  R271 and the remaining Tkk strains clustered in a profile that 
occurred below that of the baseline H37Rv. R35 and Kzn 605 had profiles located above that of the standard, 
with increased magnitude in their difference. This is consistent with the melting point temperatures in figure 3. 
In summary, the rifampin results shows that the assay could detect six out of seven of the strains with 
mutations, a percentage sensitivity of 86%. The Tkk-062 strain result is classified as a false negative, 
as it contains a mutation but was not detected with the rifampin assay. Specificity estimates cannot be 
calculated because the assay had no drug susceptible strains in the test panel. Thus, thesestrains are 
suitable for evaluation of the rifampin assay on the Light Forge system.  
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3.1.2 Isoniazid resistance assay 
katG  
 
Figure 5: Cycle threshold values achieved during amplification of the katG gene for the various 
laboratory strains. The graph above shows the amplification of a segment of the katG gene in the 
M.tuberculosis panel. The average Cq values were less than 29, suggesting that amplification was efficient 
enough for HRMA. The reaction data shows that with the exception of R35, the different M.tuberculosis strains 
amplified the katG product to detectable levels between cycles 17 to 20. This suggest that all the other strains 
with the exception of the late amplifier R35 (Cq of 26) accumulated the PCR product at almost similar rates . 
The non-template control showed no appreciable amplification, thus the findings are reliable and is 














H37Rv R 35 Kzn 605 R 271 Tkk-050 Tkk-062 Tkk-043 Tkk-039 
89.94 89.95 89.92 89.96 89.89 89.92 89.94 89.75 
89.9 89.83 89.93 89.95 89.91 89.85 89.76 89.75 
90.01 89.83 89.98 89.95 89.9 89.86 89.83 89.82 
89.99 89.78 89.87 90.07 89.82 89.98 89.78 89.81 
90.02 89.86 89.85 90.01 89.87 89.85 89.75 89.84 
89.98 89.81 89.89 89.94 89.89 89.84 89.78 89.72 
89.89 89.81   89.94 89.87 89.83 89.78 89.79 
89.94 89.73   89.92 89.79 89.91 89.8 89.67 
Count 8 8 6 8 8 8 8 8 
Mean 89.96 89.83 89.91 89.97 89.87 89.88 89.80 89.77 
Stdev 0.049 0.064 0.047 0.049 0.042 0.052 0.061 0.057 
Sem 0.0061 0.008 0.0078 0.0061 0.0052 0.0065 0.0076 0.0071 
Table 5: Melting point temperatures for the katG amplicon of the test M.tuberculosis strains. Melting 
point temperatures of the katG amplicons for the various M.tuberculosis test strains. The mean melting point 
temperatures ranged from 89.77 to 89.97°C and the standard deviation from 0.042 to 0.064°C. In all of the test 
strains, 68% of the observed Tm values were with the range of ± standard deviation, suggesting that the data is 
normally distributed. Kzn 605 had two of replicates where no amplification was detected for unclear reasons. In 
conclusion, the observed variation in the Tm amongst the test strains is result of the sequence of the amplicons 









Figure 6: Pictorial variation of the melting point temperatures of the katG amplicons generated from the 
M.tuberculosis strains. The variation of the melting point of the amplicons figure 6 above. R35 and Tkk-043 
are in the same temperature region that is slightly lower than that of H37Rv. All the other strains with the 
exception of R271 (which had no mutation detected by Sanger sequencing as shown in table 8), showed a 
similar melting point temperature. Tkk-039 displayed a curiously lower melting point temperature. In summary, 
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Figure 7: Difference plot generated from the dissociation curves of the katG amplicons of the test 
M.tuberculosis strains. Only two dissociation profiles were observed for the M.tuberculosis amplicons of the 
katG gene. R35 showed a distinct profile but the same was not observed for Tkk-039. Thus a disparity is 
observed between the melting temperature graph (figure 6) and figure 7. All the other strains had a profile that 
was similar to H37Rv, consistent with the sequencing results in Table 8. The baseline signal for H37Rv was 
clustered with all the other strains, making it difficult to isolate the profiles. 
In summary, one out of six strains was detected, a sensitivity of 17%. All the test strains are 
classified as false negative results as table 8 shows that they contain the mutations. Due to the low 









Figure 8: Cycle thresholds of the various M.tuberculosis strains during mab-inhA amplification. The 
pictogram above detailed how each of the M.tuberculosis DNA samples behaved during during the 
amplification process. From the statistical analysis, the reactions  at average Cq values less than 29. R35 was a 











Table 6: Melting point temperatures of the mab-inhA amplicons from various test M.tuberculosis strains. 
The table above shows the variation in the melting point temperature for amplicons of mab-inhA gene amplified 
from different test samples. The melting point temperature varied from 90.5 to 90.7°C, with small estimates of 
standard deviation and error observed amongst the replicates i.e. over a 1000-fold less than the mean. Again, for 
the test strains, 68% of the observed Tm values are within the first standard deviation, thus the data is normally 
distributed. It was concluded that the variations in the Tm were a result of the differences between the amplicons 



















90.67 90.51 90.65 90.68 90.55 90.52 90.69 90.74 
90.56 90.49 90.59 90.68 90.51 90.45 90.61 90.73 
90.6 90.5 90.62 90.68 90.5 90.46 90.69 90.67 
90.66 90.5 90.64 90.8 90.54 90.51 90.71 90.68 
90.69 90.52 90.67 90.67 90.53 90.51 90.67 90.7 
90.58 90.48 90.59 90.6 90.49 90.5 90.64 90.71 
90.56 90.48 90.55 90.6 90.47 90.49 90.64 90.65 
90.6 90.52 90.62 90.58 90.51 90.51 90.65 90.72 
Count 8 8 8 8 8 8 8 8 
Mean 90.62 90.5 90.62 90.66 90.51 90.50 90.66 90.7 
Stdev  0.051 0.016 0.039 0.070 0.027 0.026 0.033 0.031 
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Figure 9: Visual variation of the melting point temperatures of the M.tuberculosis strains at the mab-inhA 
locus.The visual representation of the melting point temperature. Two strains, Tkk-043 and Tkk-039 were 
within a temperature region above that of H37Rv. Tkk050,Tkk062 and R35 were located in melting temperature 
regions below  H37Rv. R35 did not have any detectable mutation as shown in table 8.The class one mutation in  
Kzn 605 showed no detectable difference from H37Rv. The remainder of the strains, which had no detectable 












Figure 10: Difference plot generated from the thermal dissociation curves of the various M.tuberculosis 
strains at the mab-inhA loci. As shown in Figure 9, only two profiles were observed on the difference plots. 
R35, which had no mutation in this region as ascertained by sanger sequencing, had an unusual profile. The rest 
of the samples have the same identical profile with H37Rv, in spite of having mutations that were skewing the 
melting point temperature as shown in figure 9.  
In summary, it is quite clear that the findings from the melting temperature graph and the difference 
plot do not easily align. Based on the difference plot, the isoniazid assay at the mab-inhA gene had 
0% sensitivity. Due to the failure of the assay to detect the resistance-linked mutations, the assay was 







3.1.3  Ofloxacin resistance results 
gyrA  
 
Figure 11: Cycle threshold numbers for each of the M.tuberculosis strains observed during amplification 
of the gyrA amplicon. The figure above shows the average cycle threshold for pooled replicates of each of the 
test DNA samples. The reactions produced detectable quantities of product between cycles 18.5 to 24.5. As all 
the Cq values were below 29, thus it was concluded that the amplification was efficient. As shown in the 
preceding figures, R35 appears to be a late amplifier, with a Cq value of 24.5. The non-template control showed 



























91.92 91.96 91.78 91.94 91.94 92.04 92.02 92.07 
92.01 91.96 91.73 91.95 91.98 91.92 91.93 91.98 
91.81 92.03 91.7 91.9 92.02 91.93 92.08 92 
91.99 92.05 91.79 91.93 92.01 91.9 91.97 92 
91.84 92 91.74 91.94 92.01 91.98 91.93 92.03 
91.95 92.01 91.67 91.89 91.96 91.91 91.97 91.97 
91.99 91.94 91.69 91.94 91.88 91.97 91.92 91.98 
  91.91 91.7   92.19 92.04 91.99 91.98 
Count 7 8 8 7 8 8 8 8 
Mean 91.93 91.99 91.73 91.93 91.97 91.95 91.97 92.00 
Stdev 0.078 0.041 0.045 0.023 0.050 0.050 0.058 0.035 
Sem 0.030 0.014 0.016 0.0087 0.018 0.018 0.021 0.012 
Table 7: Melting point temperatures from the dissociation curves of the gyrA amplicons of the 
M.tuberculosis strains. The table above shows how the melting point temperature for each replicate of the 
M.tuberculosis strains varied during the melt analysis. The average melting point temperature ranged from 91.95 
to 92°C. Consistent with the theoretical assumptions of the normal distribution, 68% of the observed 
temperatures are with a single standard deviation. This shows that the variation observed was normal and not 
reflective of inaccurate measurements of the Tm. Low estimates of the standard error show that the average Tm 




































































Figure 12: Visual distribution of the melting point temperatures of the gyrA amplicons of the test 
M.tuberculosis strains. The figure above is a visual depiction of the melting point temperature of the various 
M.tuberculosis test strains. The majority of the test strains were within the same Tm region as the standard 
H37Rv. The only exception was Kzn 605, which had a reduced melting point temperature region located below 
that of H37Rv. The other strains were located within the same temperature region with H37Rv, suggesting the 








Figure 13: Difference plot generated from the dissociation curves of the various amplicons from the gyrA 
loci. The figure above shows the difference plot for the various M.tuberculosis strains at the gyrA region. R35 
had profile that spanned up and down that of the H37Rv, in spite of not having any mutation within this region 
as shown by Table 8. Kzn 605 showed a profile that was very distict from that of H37Rv. The profile was 
located below that of the H37Rv baseline, consistent with the observation made in figure 12. Kzn 605 had two 
mutations, which skewed the melting point temperature. Unfortunately, all the other strains on the test panel had 
a mutation, which is not linked to ofloxacin drug resistance (S95T). 
In summary, the ofloxacin managed to detect resistance with a 100% sensitivity. The presence of the 
non-synonymous mutations meant that the other strains could were not suited for use in the resistance 
detection assay. In spite of the perfect sensitivity, the ofloxacin assay proved feasible for one strain, 





3.2 HRMA with Light Forge 
Following on from the findings from the initial phase, the rifampin assay was used to study drug-
linked mutations in the test panel of M.tuberculosis strains with the Light Forge device. The initial 
image shows the 2D appearance of the microfluidic chip under bright field microscopy view. 
Followed by a snapshot view of the chip before and after product amplification using the green 
fluorescent protein (GFP) filter. These images are  acquired using a LabView based system. They are 
processed using a Matlab script to produce the amplification, melt and the derivative plots. The 
current chip can only be used to test one strain per reaction, with the other reactors being occupied by 
the standard and non-template control. 
Following on from phase 1, the amplification plots serve to show efficient amplification of the 
product. The microfluidic chip used had 20 reactors thus an identical assay of the Cq values is not 
possible. An empirical rule is used, such that if the fluorescence picks up before the 20
th
 cycle i.e it 
has reached the logarithmic amplification stage (exponential phase), the reaction is considered as an 
efficient amplifier. No signal from the non-template control is ideal. 
Melt curves then follow, which show the progression of the gradual denaturation of the amplicons. 
These plots are used to detect variants from the H37Rv. Ideally the melt curves should show that the 
non-template control has a lower melting point temperature than the reaction with DNA 
124
.  
Derivative peaks generated from the melt curve data are presented. These show the negative 
derivative of the normalized melt curve data. The presence of a mutation is shown by the of shifting 
of the peak by the test strain in comparison to H37Rv. The peak for the test and standard strains are 
expected to be located at a higher temperature in comparison to that of the non-template control. Non-
template control peaks located in the same region as the desired product strong suggest the possibility 
of contamination. 
The results are then conclude by a visual depiction of the Tm values for each of the tested strain. This 
graph is useful in deciding if a test strain is assigned as mutant or wild type together with, the 




Figure 14: Bright field aerial view of the 20-reactor microfluidic chip. This picture shows how the chip 
looks like when the reagents are being loaded. The silver objects protruding from each circular aperture are the 










    Cycle 1 Image at 60°C step                                                           Cycle 35 Image at 60°C step 
                                      
Figure 15: Appearance of the microfluidic chip pre and post amplification using the GFP module on the 
fluorescent filter wheel. The images above show the change in the fluorescence signal during the amplification 
of the PCR mix containing M.tuberculosis DNA. The images were acquired using a CCD camera controlled by 
a computer program developed in house i.e. Light Forge system. Light Forge uses a temperature feedback 
system that captures images when easily programmable temperature and time thresholds are attained. The 




is a confirmation that amplification was 
occurring on the chip. It should be noted that two reactors with the non-template control showed no 
amplification thus remained dark squares, showing that contamination was not an issue in the experiment.  


























Figure 16 : Amplification profile of R35 and H37Rv rpoB amplicons in the Light Forge device. The above 
graph is showing the progression of the amplification process, both samples  reached the exponetial 
amplification phase before the 20
th
 cycle. Product is detected for the non-template control in later cycles. This 
suggests the presence of primer dimers, but this can only be concluded from the melt curve data. Thus from this 
























Figure 17: Melt curves comparing R35 and H37Rv amplicons at the rpoB loci. The above graph shows the 
denaturation profile of the amplicons during the melt curve assay. R35 samples melt at a later temperature in 
comparison to H37Rv. The non-template control melts at a temperature before both the test amplicons. One of 
the R35 replicates appears to overlapp with the melt curves of H37Rv. It was concluded that the amplicons from 























Figure 18: The Derivate plot for R35 and H37Rv rpoB amplicons. H37Rv showed peaks that were lower 
than the peaks observed for H37Rv. The non-template control showed peaks that located at lower 





          
 
Figure 19: Pictorial representation of the melting point temperatures of H37Rv and R35. The illustration 
above shows the variation of the melting point temperature of R35 compared with H37Rv. The replicates show 
that the temperatures were distinct; a 2°C difference compared to the 0.21 observed using the Light Cycler96 
system. One outlier was observed in the R35 sample, with a low Tm of 83°C. The non-template showed a 
melting profile lower than the target amplicon thus the findings are reliable. 
Thus in conclusion, Light Forge managed to detect the mutations within the rpoB amplicon of R35, 
























































Figure 20: Amplification of the rpoB amplicons from Kzn 605 and H37Rv. Both samples reached the 
exponential phase before the 20
th
 cycle. The non-template control reactions reached the exponential phase 
around the 24
th
 cycle. The positive reaction in the either non-template controls suggest that the primer dimers 
amplified or there was contamination but this is concluded by observation of the subsequent plots.  
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Figure 21: Melt curve profile from the amplification of the rpoB amplicons of Kzn 605 and H37Rv. The 
graph above shows how the amplicons from Kzn 605 and H37Rv denatured during the melting process. Kzn 
605 amplicons seem to have a higher melting point temperature in comparison to the H37Rv samples. The graph 
shows that the non-template control reactions had lower melting point temperatures. Both Kzn 605 and H37Rv 
showed a biphasic melting curve profile which, in which the product appears to melt in two stages. It can be 

























Figure 22: Derivative plot for the H37Rv and Kzn 605 rpoB amplicons. The graph above shows the 
derivative plot from the melt data of H37Rv and Kzn 605. The graph shows two distinct peaks for the replicates 
of sample, There is no peak in the non-template control with the region were the target amplicon. Thus it can be 
concluded that the reaction was successful in differentiating the amplicons. Both samples showed a minor peak 




Figure 23: Visual variation of the melting point temperature of H37Rv vs Kzn 605 at the rpoB amplicon. 
The figure above shows the differences in the melting point temperature between H37Rv and Kzn 605. There is 
a clear and well defined difference between the general melting point temperatures of these two strains of about 
1°C. This about a 1.5 fold increase from the 0.62°C observed on the Light Cycler96. However, this difference 
was lower than expected considering that Kzn 605 showed a higher temperature difference than that of R35 on 
the Light Ccyler96 system. The lower Tm values from the non-template controls affirm that the reaction was not 
affected by contamination, as the positive non-template reaction was due to primer dimers. 
In summary, it can be concluded that the Light Forge system can detect mutations linked to drug 





















































Figure 24:  Amplification profile of H37Rv and Tkk-062 samples at the rpoB loci. The above graph shows 
the amplification profile of Tkk-062 and H37Rv. The graph shows that both H37Rv and Tkk-062 reached the 
exponential phase around the 17
th
 cycle. One of the non-template control replicates reached the exponential 
phase around the 27
th
 cycle. A positive control of gyrA amplified from H37Rv was used as a positive control. 
Thus, it was concluded that the amplification process occurred efficiently. The positive reaction in the non-
template control can be due to contamination or the presence of primer dimers, but the subsequent plots will 
assert this.  
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Figure 25: Melt curve of Tkk-062 and H37Rv at the rpoB region. The above figure shows the differences 
in melting profile of the standard strain vs the test Tkk-062. The amplicons showed melt curves that were 
almost identical with minor deviations. The Tkk-062 shows a profile that is skewed to the right of H37Rv 
because of the mutations. Both samples showed a curious  The gyrA amplicons showed melting point 
temperatures much higher than rpoB. From this profile, it is difficult to ascertain with high confidence if the 

























Figure 26: Derivative plot showing the melting point peaks of H37Rv and Tkk-062. The derivative plots 
show the location of the melt derivative curve peaks for the different samples. H37Rv and Tkk-062 show 
slightly different locations of the melt peaks around the 82°C. There is a hint of deviation between the samples 
but it is not easily discernible. The gyrA amplicon shows melt peaks located at a higher temperature around 
86°C. The non-template control shows that the positive reaction was because of primer dimers. Thus, it is 
concluded that the derivative peaks managed to detect the slight variation in the melting point temperature albeit 













Figure 27: Melting point temperature of H37Rv vs Tkk-062 at the rpoB loci. The figure shows a small 
difference between the melting point temperature of H37rv and that of Tkk062. The difference in the Tm values 
of H37Rv and Tkk-062 of approximately 0.1°C (10-fold increase) compared to 0.01°C on the Light Cycler96. 
The gyrA positive control showed a very high Tm value of 85.2°C as opposed to 91.3°C observed on the Light 
Cycler96. The non-template controls show an expected lower melting point temperature, thus the positive 
reaction in the non-template controls was a result of the primer dimers.  
In summary, the Light Forge assay could detect the mutation  linked to drug resistance. It should be 
noted that this finding is a low confidence positive result due to diminished temperature difference. 




























   







Figure 28: Pictorial summary of derivative peak temperatures as detected by the Light Cycler96 and the 
Light Forge system. The above graph shows the differences in the average melting point differences observed 
for the rpoB amplicons  of H37Rv  and the selected strains. In all iterations,  the Light Forge  device amplified 
the size of the deviation detected by the Light Cycler96. Consistently large deviations greater than 0.5°C were 
observed with the microfluidic system when used to detect class 1 mutation in R35 and Kzn 605.   Light Forge 
also outperformed the Light Cycler96 when used to detect the class 4 mutation present in Tkk-062. In summary, 
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CHAPTER 4: DISCUSSION  
Resistance to rifampin has been largely attributed to mutation of bases in the rpoB  81bp region, from 
codons 507 to 533 
53
. This region accounts for 95% of the incidence of rifampin resistance
264
. The 
remaining 5% is attributed to mutations outside this region such as  V176F or  Rv2629 gene 
269
. 
Resistance to  isoniazid, is determined by multiple genes such as katG, mab-inhA promoter region, 
kasA, oxyR and aphC,  mainly as compensatory mechanisms by which the M.tuberculosis averts drug 
pressure 
53
. The katG gene is thought to account for 50 to 70% of isoniazid resistance isolates, whilst 
mab-inhA is  responsible for 15 to 20% of the resistance isolates
53
. Combining these two in a 
diagnostic assay increases the chances of detecting strains of M.tuberculosis with resistance to the 
drug. Quinolone resistance is due to mutations in the gyrA gene, which has been reported to be the 
cause of this phenotype in 42 to 85% of the cases 
270,271
.  
In this study, six out of the seven (86% sensitivity) strains with the rpoB mutations were detected 
using the Light Cycler96 system, producing four distinct profiles during the rifampin resistance assay. 
The only exception was Tkk062, which registered as a susceptible strain. This was caused by the 
presence of a class 4 mutation (A to T) at codon 526, which involves  switching of the nucleotides 
from one strand to another, thereby causing a diminished thermal aberration 
270
. Literature suggests 
that the most frequently observed mutations in the rpoB region are located on codon 531, which was 
not the case for this panel of test strains
272
. 
For isoniazid resistance, the two genes with the most understood influence, katG and mab-inhA were 
separately analysed. As shown by the difference plot in Figure 7, HRMA managed to detect one out 
of a possible six (17% sensitivity) mutations in the katG region. However, a rather interesting profile 
was observed in figure 6, where R35 and Tkk043, which contain the same mutation at codon 315 (as 
shown in table 8), appear to have an identical temperature profile. However, this deviation is 
undetectable in the difference plot. It is difficult to assign resistance based on temperature variation, 
especially since the Light Cycler96 technical specification document states that the melting 
temperature can vary with ±0.4°C. All the other strains with the exception of R271, showed a similar 
melting point temperature as they all harboured the guanine to cytosine mutation which is associated 
with a low temperature change of less than 0.4°C 
270
. Tkk039 displayed a curiously lower melting 
point temperature in spite of harbouring the same S315T mutation as Kzn 605, Tkk050 and Tkk039. 
For the mab-inhA promoter region, Light Cycler96 detected none of the three mutants, inexplicably 
detecting R35 as mutant, even though it has no mutation in this region. Careful analysis of the actual 
melting point temperatures show a more expected profile in figure 9, with the mutants clearly 
deviating from the reference strain. The apparent deviation between the difference plot and the 
melting point temperature plot suggests that more optimisation is required to establish which is more 
superior, as the results for both these genes were rather confounding. Consistent with these findings, a 
study by Yadav et al reported that two strains which were shown to be isoniazid susceptible via both 
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culture methods and sequencing, produced variant HRMA profiles
120
. These deviations could have 
been because of instrument, reagent or even PCR variations. In light of these drawbacks, these two 
genes were not used on the microfluidic platform. 
For ofloxacin resistance, the gyrA gene was used and managed to detect the only strain with the 
resistance-linked mutations, which was the Kzn 605. The rest of the test strains had the S95T 
mutation, a rather unfortunate finding, as this is a non-synonymous mutation. This means that the 
particular mutation has no bearing on the drug resistance profile of the M.tuberculosis. It is commonly 
detected in M.tuberculosis strains of the beijing genotype 
271
. This can be addressed by using H37Ra 
as the standard strain, as it contains this mutation or developing primer sets that circumvent the 95 
codon 
167
. Kzn 605 showed a very distinct profile in the difference plot as shown in figure 13, which 
corresponded moderately well with the melting point graph shown in figure 12.  As observed during 
the isoniazid resistance assay, R35 behaved unexpectedly as it gave a distinct profile in the difference 
profile but a typical orientation in the melting point temperature plot. Again, the disparities observed 
when probing mutations with the commercial system for this gene meant that the strains could not be 
studied using the microfluidic system. It is interesting to note that  R35  amplified  late  for the katG, 
mab-inhA and gyrA reactions as shown by figure 5, figure 8 and figure 11 respectively. This suggests 
that the R35 might have contained a constituent that somehow delayed the amplification process. This 
is feasible considering that the sample originates from a complex multi-step DNA extraction protocol 
with several salts and solvents that can affect the activity of the polymerase. 
Based on the results from the conventional HRMA Light Cycler96 system, further testing of the test 
strains was done for the rpoB gene on the Light Forge device. R35 was clearly distinguished from 
H37Rv as shown in figure 17-19. An impressive observation was that the melting point temperature 
difference between the strains was approximately 2°C, a 10-fold increase in comparison with the 
Light Cycler96 system as shown by the average melting point temperatures in table 4. A similar 
distinction was observed when Kzn 605 was compared to the H37Rv, in which the melting point 
temperature difference was 1°C as opposed to the 0.62°C as observed in the conventional system. 
However, this was unexpected, as Kzn 605 had a larger melting point deviation on the commercial 
system than R35. This can be explained by the mechanical variation often observed during HRMA as 
a result of suspected non-uniformity in the heating and optical system 
273
. Tkk-062 yielded a very 
small thermal deviation of approximately 0.1°C when compared to H37Rv as shown in figure 18, 
again a tenfold increase from the largely insignificant 0.01°C observed on the commercial system. 
Examination of figure 22 and 26 shows a minor peak in the derivative plots after the pronounced 
peaks, an occurrence not observed in the commercial system. Green suggested that appearance of 
double peaks is a result of either amplification of  short length chimeric products or background 
nucleic acids depending on the sample source
113
. These claims were discounted as the non-specific 
products melt before the pronounced peak and the DNA originated from pure cultures of the strains as 
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opposed to mammalian samples where this occurrence is frequent. A more plausible explanation is 
that the various electronic components used during data acquisition might be subject to random 
deviations because of fluxes leading to an artificial peak. Considering the fact that Wi-Fi signals are 
abundant in the laboratory, a manner to shield the system from this interference should be considered 
in a bid to improve the measurement. 
These findings suggest that the microfluidic system, when properly optimized could yield better 
analytical performance of the HRMA that can ultimately lead to adoption of this protocol in the 
clinical setting. A study by Phowlat et al reported the use of TaqMan array card which can perform 
the same HRMA on 10 genes linked with M.tuberculosis resistance 
163
. The study used HRMA in 
combination with mutation specific hydrolysis probes, using the former to detect unknown mutations 
on a platform that performed 48 separate reactions, with a volume of 1µl, for eight separate samples. 
Such a device is brilliant in principle but further designing is required for this system to be adaptable 
to the emerging market where this innovation is needful when the cost of the probes, machinery and 
maintenance services are considered, creating a void  systems such as the Light Forge can fill.  
In spite of the potential that such approaches possess in terms of M.tuberculosis diagnosis, HRMA 
needs to address the several drawbacks. The saturating dyes used to detect the PCR product are not 
specific to any sequence thus sometimes atypical PCR products are detected 
169
. HRMA is dependent 
on a high quality and quantity input DNA sample, which is not guaranteed when working with clinical 
samples such as sputum.  Such a challenge can be avoided by adding a sputum processing module on 
a microfluidic chip that can extract DNA 
274
, which would help in the capture and detection of wild 
strains of tuberculosis. Alternatively, the cheap methods currently used to decontaminate sputum 
samples can be used in conjuction with PCR additives that enhance amplification such α-casein or 
BSA,  increasing sensitivity of the assay 
275
. Nagai et al showed in a study that wild strains are 
detectable with very high accuracy with HRMA using strains from Mie-Chuo Medical centre, 
confirming results with culture and sanger sequencing
162
. 
 HRMA is also prone to the detection of false positives 
276
 i.e. silent mutations which are not actually 
linked with drug resistance, suggesting that more research is required to fully comprehend the 
mechanisms that lead to drug tolerance. As a consequence, molecular assays still require phenotypic 
testing before a high confidence resistance profile can be confirmed 
277
. Since molecular assays target 
nucleic acids, there is a high chance of them detecting DNA from dead M.tuberculosis cells which 
would be culture negative as reported in the study by Rachow and et al with the Gene Xpert system 
274




Light Forge demonstrated its ability to detect mutations that are linked to rifampin resistance in the 
test M.tuberculosis strains. This ability can be translated to an affordable, quick and easily accessible 
assay that can be used in resource poor communities, as the platform is cost conscious as reflective in 
the use of saturating dyes and miniaturization. With reported increases in the cases of drug resistance 
277
, there is a need for efforts to be rapidly channelled towards providing patients, within the emerging 
markets, a diagnostic solution with the potential to positively shift the Tuberculosis pandemic. 
Recommendations 
The first recommendation would be to include other genes that are associated with drug resistance 
such as gyrA,gyrB katG,mab-inhA, embB, pncA, rrs etc in a bid to understand the profile of the 
M.tuberculosis pathogen. This can be an extension of the concept of personalized medicine, in which 
the treatment plan is fully instructed by the patient specific profile 
278
. This can lead to more powerful, 
precise and predictable health management systems at a very personal level. Such an approach would 
also require patient genetic and environmental backgrounds to be considered as these also play a key 
role in how patients respond to any given treatment
279
. This would require an increase in the number 
of reactors to accommodate the other targets and re-optimisation but it is quite easily achievable as all 
the expertise required are available in house. An increase in the number of test strains is needful, 
especially increasing the number of strains lacking the mutation to have a much more reliable 
specificity estimate. Following from the reviewed articles summarised in table 2, a minimum number 
of 50 samples in the assay can easily achieve the desired specificity.  
The second recommendation would be to design a microfluidic device that can probe the various 
mechanisms of heteroresistance in M.tuberculosis 
280
. This is when a host is simultaneously infected 
with drug resistant and drug susceptible strains of M.tuberculosis 
281
. It is suggested that this is a 
preliminary phase to full resistance but is often missed due to detection limits of the current methods. 
This is shown by the fact that a mutant strain of M.tuberculosis can only be detected if it is above 65% 
of the population of microorganisms when, for example, using the Gene Xpert device 
282
. A 
microfluidic device with an increased number of partitions which can capture, amplify and detect 
sequence variants would be an indispensable tool for understanding the significance of this 
occurrence. Phowlat and et al have already carried out preliminary work by performing digital PCR 
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Mutations detected by Sanger sequencing HRMA result                
(LightCycler®96) 
HRMA result  
(Light Forge) 
Mutation Class Phenotype 
rpoB mab-inhA katG gyrA rpoB mab-
inhA 
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V WT WT V V 1 4 3 1&3 R R R 
R271 TCGTTG 
(S531L) 




V WT WT WT NT 1 - - 3 R R S 
Tkk-050 CAC TAC 
(H526Y) 
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V WT WT WT NT 1 - 3 3 R R S 
V-variant, WT-wild type/ none variant, ND- none detected, NT- not tested, R-resistant, S-susceptible 
The graph shows a comparative summary of the drug susceptibility testing using the Light Cycler96, Light Forge, Sanger sequencing and phenotypic methods. In spite of some cases of discordance, a high degree of agreement across the 

















Table 9: Quantity and purity of M.tuberculosis DNA samples. The A260/A280 for pure DNA preparations is around 1.8.  
The table above shows the quantity and purity of the DNA samples used in the assay. The initial extracts were measured for the total DNA and purity using the A260/A280 number.  All samples were then adjusted to contain 200ng per 
reaction by diluting with TE Buffer according to sample specific instructions in the table. This meant that the same volume and quantity of DNA is added per reaction to remove variability that these two factors might possibly introduce. 
Thus for all the genes studied by all the molecular DST methods used these adjusted DNA samples for unifor







DNA (ng) content 
per reaction 
Volume of sample 
added 
Volume  







Final A260/A280 Volume added to 
PCR master mix 
(µl) 
H37Rv 114 1.91 200 1.75 98.25 0.8 1.98 5 
R35 30.6 1.88 200 6.5 93.5 1.9 1.44 5 
Kzn 605 34.5 1.93 200 5.8 94.2 1.1 1.74 5 
R271 29.6 1.92 200 6.8 93.2 0.9 1.53 5 
Tkk-050 16.4 1.91 200 12.2 87.8 1.5 1.59 5 
Tkk-062 33.2 1.89 200 6.02 94 0.8 1.52 5 
Tkk-043 97.6 1.95 200 2.05 97.95 0.7 1.34 5 
Tkk-039 33.8 1.93 200 5.92 94.08 1.1 1.29 5 
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